US20040101928A1 - Lipolytic enzyme genes - Google Patents

Lipolytic enzyme genes Download PDF

Info

Publication number
US20040101928A1
US20040101928A1 US10/250,824 US25082403A US2004101928A1 US 20040101928 A1 US20040101928 A1 US 20040101928A1 US 25082403 A US25082403 A US 25082403A US 2004101928 A1 US2004101928 A1 US 2004101928A1
Authority
US
United States
Prior art keywords
seq
ala
ser
mature peptide
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/250,824
Inventor
Noriko Tsutsumi
Jesper Vind
Shamkant Patkar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novozymes AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to NOVOZYMES A/S reassignment NOVOZYMES A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PATKAR, SHAMKANT ANANT, VIND, JESPER, TSUTSUMI, NORIKO
Publication of US20040101928A1 publication Critical patent/US20040101928A1/en
Priority to US11/474,151 priority Critical patent/US7271139B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D8/00—Methods for preparing or baking dough
    • A21D8/02—Methods for preparing dough; Treating dough prior to baking
    • A21D8/04—Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes
    • A21D8/042—Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes with enzymes
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38627—Preparations containing enzymes, e.g. protease or amylase containing lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase

Definitions

  • the present invention relates to a method of generating diversity into lipolytic enzymes by the use of the so-called family shuffling of homologous genes.
  • the invention also relates to polynucleotides for use in the method, and to lipolytic enzymes encoded by the polynucleotides.
  • the lipase of Thermomyces lanuginosus (also known as Humicola lanuginosa ) is known to be useful for various industrial purposes such as detergents and baking (EP 258068, WO 9404035). Its amino acid and DNA sequences are shown in U.S. Pat. No. 5,869,438.
  • novel lipolytic enzyme genes with a high homology to the T. lanuginosus lipase gene and are thus well suited for use in gene shuffling.
  • novel genes are shown as SEQ ID NO: 3, 5, 7, 9 and 11.
  • Identity tables for some protein and DNA sequences are shown below. The novel sequences are identified as follows:
  • Talthe1M SEQ ID NO: 3 and 4 from Talaromyces thermophilus.
  • Theiba1M SEQ ID NO: 5 and 6 from Thermomyces ibadanensis.
  • Taleme1M SEQ ID NO: 7 and 8 from Talaromyces emersonii.
  • Talbys1M SEQ ID NO: 9 and 10 from Talaromyces byssochiamydoides.
  • Thelan1M Lipase from Thermomyces lanuginosus , SEQ ID NO: 1 and 2.
  • Asptub2M EMBL A84589 Lipase from Aspergillus tubingensis.
  • Aspory3M EMBL E16314 Phospholipase A1 from Aspergillus oryzae.
  • Aspnig2M EMBL A90761 Lysophospholipase from Aspergillus niger.
  • the invention provides a method of generating genetic diversity into lipolytic enzymes by family shuffling of two or more homologous genes which encode lipolytic enzymes.
  • One gene encodes a lipolytic enzyme with at least 90% identity to the T. Ianuginosus lipase, and another gene encodes a lipolytic enzyme with 55-90% identity to the T. lanuginosus lipase.
  • the DNA shuffling technique Is used to create a library of chimeric shuffled genes, and this is expressed in a suitable expression system and the expressed proteins are screened for lipolytic enzyme activity.
  • the expressed proteins may further be screened to identify lipolytic enzymes with improved properties.
  • the invention also provides a polynucleotide comprising a nucleotide sequence encoding a lipolytic enzyme and a lipolytic enzyme (a polypeptide with lipolytic enzyme activity).
  • the polynucleotide may be a DNA sequence cloned into a plasmid present in E. coli deposit number DSM 14047, 14048, 14049, or 14051, the DNA sequence encoding a mature peptide shown in SEQ ID NO: 3, 5, 7 or 9 or one that can be derived therefrom by substitution, deletion, and/or insertion of one or more nucleotides.
  • the polynucleotide may have at least 90% identity with the DNA sequence encoding a mature peptide shown in SEQ ID NO: 3, at least 80% identity with the DNA sequence encoding a mature peptide shown in SEQ ID NO: 5, at least 65% identity with the DNA sequence encoding a mature peptide shown in SEQ ID NO: 7, or at least 60% identity with the DNA sequence encoding a mature peptide shown in SEQ ID NO: 9.
  • It may also be an allelic variant of the DNA sequence encoding a mature peptide shown in SEQ ID NO: 3, 5, 7 or 9; or it may hybridize under high stringency conditions with a complementary strand of the nucleic acid sequence encoding a mature peptide shown in SEQ ID NO: 3, 5, 7 or 9, or a subsequence thereof having at least 100 nucleotides.
  • the lipolytic enzyme may be encoded by a DNA sequence cloned into a plasmid present in E. coli deposit number DSM 14047 or 14049, or may have an amino acid sequence which is the mature peptide of SEQ ID NO: 6 or 10, or one that can be derived therefrom by substitution, deletion, and/or insertion of one or more amino acids.
  • the lipolytic enzyme may have an amino acid sequence which has at least 80% identity with the mature peptide of SEQ ID NO: 6 or at least 60% identity with the mature peptide of SEQ ID NO: 10.
  • the lipolytic enzyme may further be immunologically reactive with an antibody raised against the mature peptide of SEQ ID NO: 6 or 10 in purified form, be an allelic variant of the mature peptide of SEQ ID NO: 6 or 10; or be encoded by a nucleic acid sequence which hybridizes under high stringency conditions with a complementary strand of the nucleic acid sequence encoding a mature peptide shown in SEQ ID NO: 5 or 9, or a subsequence thereof having at least 100 nucleotides.
  • FIG. 1 shows a PCR scheme used in Example 7.
  • Lipolytic enzyme genes of the invention may be derived from strains of Talaromyces or Thermomyces, particularly Talaromyces thermophilus, Thermomyces ibadanensis, Talaromyces emersonii or Talaromyces byssochlamydoides , using probes designed on the basis of the DNA sequences in this specification.
  • genes and polypeptides shown in the sequence listing were isolated from the organisms indicated below.
  • Strains of Escherichia coli containing the genes were deposited by the inventors under the terms of the Budapest Treaty with the DSMZ—Deutsche Sammlung von Microorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-38124 Braunschweig DE as follows: Gene and polypep- Clone de- Clone deposit
  • Source organism tide sequences posit No. date Talaromyces thermophilus ATCC SEQ ID NO: 3 and DSM 14051 8 Feb. 10518 4 2001
  • Thermomyces ibadanensis CBS SEQ ID NO: 5 and DSM 14049 8 Feb.
  • ATCC American Type Culture Collection
  • CBS Cartraalbureau voor Schimmelcultures
  • Uppsalalaan 8 3584 CT Utrecht, The Netherlands.
  • IMI International Mycological Institute, Bakeham Lane, Englefield Green, EGHAM, Surrey TW20 9TY, United Kingdom.
  • the polynucleotides to be used for recombination are two or more genes encoding lipolytic enzymes, including one with at least 90% identity and one with 55-90% identity to the T. lanuginosus lipase (SEQ ID NO: 2).
  • the poloynucleotides differ in at least one nucleotide.
  • the starting material may include the mature part of two or more (e.g. three, four or five) of SEQ ID NO: 1, 3, 5, 7 and/or 9. It may also include genes encoding two or more (e.g. three, four or five) of variants of SEQ ID NO: 2, 4, 6, 8 or 10 obtained by deleting, substituting and/or inserting one or more amino acids and/or by attaching a peptide extension at the N- and/or C-terminal. Examples of variants of the T. lanuginosus lipase are described, e.g., in U.S. Pat. No. 5,869,438, WO 9522615, WO 9704079 and WO 0032758, and similar variants can be made by altering corresponding amino acids in the other sequences.
  • any introns present in the genes may optionally be removed before the shuffling.
  • Shuffling between two or more homologous input polynucleotides may involve fragmenting the polynucleotides and recombining the fragments, to obtain output polynucleotides (i.e. polynucleotides that have been subjected to a shuffling cycle) wherein a number of nucleotide fragments are exchanged in comparison to the input polynucleotides.
  • DNA recombination or shuffling may be a (partially) random process in which a library of chimeric genes is generated from two or more starting genes.
  • a number of known formats can be used to carry out this shuffling or recombination process.
  • the process may involve random fragmentation of parental DNA followed by reassembly by PCR to new full length genes, e.g. as presented in U.S. Pat. No. 5,605,793, U.S. Pat. No. 5,811,238, U.S. Pat. No. 5,830,721, U.S. Pat. No. 6,117,679 .
  • In-vitro recombination of genes may be carried out, e.g. as described in U.S. Pat. No. 6,159,687, WO98/41623, U.S. Pat. No. 6,159,688, U.S. Pat. No. 5,965,408, U.S. Pat. No. 6,153,510.
  • the recombination process may take place in vivo in a living cell, e.g. as described in WO 97/07205 and WO 98/28416.
  • the parental DNA may be fragmented by DNA'se I treatment or by restriction endonuclease digests as descriobed by Kikuchi et al (2000a, Gene 236:159-167).
  • Shuffling of two parents may be done by shuffling single stranded parental DNA of the two parents as described in Kikuchi et al (2000b, Gene 243:133-137).
  • the lipolytic enzyme obtained by the invention is able to hydrolyze carboxylic ester bonds and is classified as EC 3.1.1 according to Enzyme Nomenclature 1992, Academic Press, Inc. It may particularly have activity as a lipase (triacylglycerol lipase) (EC 3.1.1.3), phospholipase A1 (EC 3.1.1.32), phospholipase A2 (EC 3.1.1.4), cholesterol esterase (EC 3.1.1.13) and/or galactolipase (EC 3.1.1.26).
  • a lipase triacylglycerol lipase
  • phospholipase A1 EC 3.1.1.32
  • phospholipase A2 EC 3.1.1.4
  • cholesterol esterase EC 3.1.1.13
  • galactolipase EC 3.1.1.26
  • thermostability was evaluated by means of Differential Scanning Calorimetry (DSC).
  • DSC Differential Scanning Calorimetry
  • the denaturation peak (T d ) when heated at 90 deg/hr at pH 5 is slightly above 75° C. for the lipolytic enzyme from T. ibadanensis , compared to slightly above 70° C. for the prior-art T. lanuginosus lipase.
  • the lipolytic enzyme from T. ibadanensis has optimum activity at alkaline pH (similar to the T. lanuginosus lipase) and has an isoelectric point of about 4.3 (slightly lower than the T. lanuginosus lipase).
  • the degree of homology may be determined by means of computer programs known in the art, such as GAP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wis., USA 53711) (Needleman, S. B. and Wunsch, C. D., (1970), Journal of Molecular Biology, 48, 443-45), using GAP with the following settings for polypeptide sequence comparison: GAP creation penalty of 3.0 and GAP extension penalty of 0.1.
  • the determination of homology may also be made using Align from the fasta package version v20u6.
  • Align is a Needleman-Wunsch alignment (i.e. global alignment), useful for both protein and DNA alignments.
  • the default scoring matrices BLOSUM50 and the identity matrix are used for protein and DNA alignments respectively.
  • the penalty for the first residue in a gap is ⁇ 12 for proteins and ⁇ 16 for DNA. While the penalty for additional residues in a gap is ⁇ 2 for proteins and ⁇ 4 for DNA.
  • the homologies discussed in this specification may correspond to at least 60% identity, in particular to at least 70% or at least 80% identity, e.g. at least 90% or at least 95% identity.
  • the enzyme of the invention can be used, e.g., in filtration improvement, vegetable oil treatment, baking, detergents, or preparation of lysophospholipid.
  • it may be used in known applications of lipolytic enzymes by analogy with the prior art, e.g.:
  • An enzyme with lipase activity may be used for fat hydrolysis and for modification of triglycerides and for production of mono- and diglycerides.
  • An enzyme with lipase activity may be used for interesterification of bulk fats, production of frying fats, shortenings and margarine components.
  • An enzyme with phospholipase activity (A1, A2) may be used for degumming of vegetable oils and for lysophospholipid production.
  • An enzyme with lysophospholipase activity can be used to improve the filterability of an aqueous solution or slurry of carbohydrate origin by treating it with the variant. This is particularly applicable to a solution or slurry containing a starch hydrolysate, especially a wheat starch hydrolysate since this tends to be difficult to filter and to give cloudy filtrates.
  • the treatment can be done in analogy with EP 219,269 (CPC International).
  • the lipolytic enzyme produced by the invention may be used as a detergent additive, e.g. at a concentration (expressed as pure enzyme protein) of 0.001-10 (e.g. 0.01-1) mg per gram of detergent or 0.001-100 (e.g. 0.01-10) mg per liter of wash liquor.
  • the detergent composition of the invention may for example be formulated as a hand or machine laundry detergent composition including a laundry additive composition suitable for pre-treatment of stained fabrics and a rinse added fabric softener composition, or be formulated as a detergent composition for use in general household hard surface cleaning operations.
  • a laundry detergent the variant may be effective for the removal of fatty stains, for whiteness maintenance and for dingy cleanup.
  • a laundry detergent composition may be formulated as described in WO 97/04079, WO 97/07202, WO 97/41212, PCT/DK WO 98/08939 and WO 97/43375.
  • the detergent composition of the invention may particularly be formulated for hand or machine dishwashing operations. e.g. as described in GB 2,247,025 (Unilever) or WO 99/01531 (Procter & Gamble).
  • the variant may be effective for removal of greasy/oily stains, for prevention of the staining/discoloration of the dishware and plastic components of the dishwasher by highly colored components and the avoidance of lime soap deposits on the dishware.
  • the detergent composition of the invention may be in any convenient form, e.g., a bar, a tablet, a powder, a granule, a paste or a liquid.
  • a liquid detergent may be aqueous, typically containing up to 70% water and 0-30% organic solvent, or non-aqueous.
  • the detergent composition comprises one or more surfactants, which may be non-ionic including semi-polar and/or anionic and/or cationic and/or zwitterionic.
  • the surfactants are typically present at a level of from 0.1% to 60% by weight, e.g. 0.5-40%, such as 1-30%, typically 1.5-20%.
  • the lipolytic enzyme can be used in the preparation of dough and baked products made from dough, such as bread and cakes, e.g. to increase dough stability and dough handling properties, or to improve the elasticity of the bread or cake.
  • it can be used in a process for making bread, comprising adding it to the ingredients of a dough, kneading the dough and baking the dough to make the bread. This can be done in analogy with U.S. Pat. No. 4,567,046 (Kyowa Hakko), JP-A 60-78529 (QP Corp.), JP-A 62-111629 (QP Corp.), JP-A 63-258528 (QP Corp.) or EP 426211 (Unilever).
  • the lipolytic enzyme may be used together with an anti-staling amylase, particularly an endo-amylase such as a maltogenic amylase in analogy with WO 99/53769 (Novo Nordisk).
  • an anti-staling amylase particularly an endo-amylase such as a maltogenic amylase in analogy with WO 99/53769 (Novo Nordisk).
  • the lipolytic enzyme may be incorporated in a flour composition such as a dough or a premix for dough.
  • the Aspergillus oryzae expression plasmid pCaHj 483 (WO 98/00529) consists of an expression cassette based on the Aspergillus niger neutral amylase II promoter fused to the Aspergillus nidulans triose phosphate isomerase non translated leader sequence (Pna2/tpi) and the A. niger amyloglycosidase terminator (Tamg). Also present on the plasmid is the Aspergillus selective marker amdS from A. nidulans enabling growth on acetamide as sole nitrogen source. These elements are cloned into the E. coli vector pUC19 (New England Biolabs). The ampicillin resistance marker enabling selection in E. coli of this plasmid was replaced with the URA3 marker of Saccharomyces cerevisiae that can complement a pyrF mutation in E. coli , the replacement was done in the following way:
  • the pUC19 origin of replication was PCR amplified from pCaHj483 with the primers 142779 (SEQ ID NO: 35) and 142780 (SEQ ID NO: 36).
  • Primer 142780 introduces a Bbul site in the PCR fragment.
  • the Expand PCR system (Roche Molecular Biochemicals, Basel, Switserland) was used for the amplification following the manufacturers instructions for this and the subsequent PCR amplifications.
  • the URA3 gene was amplified from the general S. cerevisiae cloning vector pYES2 (Invitrogen corporation, Carlsbad, Calif., USA) using the primers 140288 (SEQ ID NO: 37) and 142778 (SEQ ID NO: 38).
  • Primer 140288 introduces an EcoRI site in the PCR fragment.
  • the two PCR fragments were fused by mixing them and amplifying using the primers 142780 and 140288 in the splicing by overlap method (Horton et al (1989) Gene, 77, 61-68).
  • the resulting fragment was digested with EcoRI and BbuI and ligated to the largest fragment of pCaHj 483 digested with the same enzymes.
  • the ligation mixture was used to transform the pyrF E. coli strain DB6507 (ATCC 35673) made competent by the method of Mandel and Higa (Mandel, M. and A. Higa (1970) J. Mol. Biol. 45, 154). Transformants were selected on solid M9 medium (Sambrook et. al (1989) Molecular cloning, a laboratory manual, 2. edition, Cold Spring Harbor Laboratory Press) supplemented with 1 g/l casaminoacids, 500 ⁇ g/l thiamine and 10 mg/l kanamycin.
  • a plasmid from a selected transformant was termed pCaHj 527.
  • the Pna2/tpi promoter present on pCaHj527 was subjected to site directed mutagenises by a simple PCR approach.
  • Nucleotide 134-144 was altered from SEQ ID NO: 39 to SEQ ID NO: 40 using the mutagenic primer 141223 (SEQ ID NO: 41).
  • Nucleotide 423-436 was altered from SEQ ID NO: 42 to SEQ ID NO: 43 using the mutagenic primer 141222 (SEQ ID 44).
  • pMT2188 The resulting plasmid was termed pMT2188.
  • Plasmid pENI1861 was made in order to have the state of the art Aspergillus promoter in the expression plasmid, as well as a number of unique restriction sites for cloning.
  • a PCR fragment (app. 620 bp) was made using pMT2188 (see above) as template and the primers 051199J1 (SEQ ID 45) and 1298TAKA (SEQ ID 46).
  • Plasmid pENI1902 was made in order to have a promoter that works in both E. coli and Aspergillus. This was done by unique site elimination using the “Chameleon double stranded site-directed mutagenesis kit” as recommended by Stratagene®.
  • Plasmid pENI1861 was used as template and the following primers with 5′ phosphorylation were used as selection primers: 177996 (SEQ ID 47), 135640 (SEQ ID 48) and 135638 (SEQ ID 49).
  • the 080399J19 primer (SEQ ID NO: 50) with 5′ phosphorylation was used as mutagenic primer to introduce a ⁇ 35 and ⁇ 10 promoter consensus sequence (from E. coli ) in the Aspergillus expression promoter. Introduction of the mutations was verified by sequencing.
  • Plasmid pENI1960 was made using the Gateway VectorTM conversion system (Lifetechnology® cat no. 11828-019) by cutting pENI1902 with BamHI, filling the DNA ends using Klenow fragment polymerase and nucleotides (thus making blunt ends) followed by ligation to reading frame A GatewayTM PCR fragment. The cloning in the correct orientation was confirmed by sequencing.
  • YPG 4 g/L Yeast extract, 1 g/L KH2PO4, 0.5 g/L MgSO4-7aq, 5 g/L Glucose, pH 6.0.
  • strains of Thermomyces ibadanensis, Talaromyces emersonii, Talaromyces byssochlamydoides , and Talaromyces thermophilus were used as a genomic DNA supplier. Each strain was cultivated in 100 ml of YPG at appropriate temperature for several days. Mycelia was harvested and ground in liquid N 2 . It was suspended with 2 ml of 50 mM Tris-HCl (pH8.0) buffer including 100 mM NaCl, 25 mM EDTA, and 1% SDS and then 12 ⁇ l of proteinase K (25 mg/ml) was added. The suspension was incubated at 65° C. for 30-60min.
  • Tris-HCl pH8.0
  • Phenol extraction was done to remove proteins and DNA was precipitated by 0.7 volume of isopropanol. The precipitate was dissolved with sterilized water and RNase was added. After Phenol/isoamylalcohol extraction, DNA was precipitated by EtOH.
  • PCR reactions on each genomic DNA was done with HL 2 and HL12 (SEQ ID NO: 51 and 52) or HL2 and HL6 (SEQ ID NO: 51 and 53) designed based upon alignment lipases.
  • Step Temperature Time 1 94° C. 1 min 3 50° C. 1 min 4 72° C. 2 min 5 72° C. 10 min 6 4° C. forever
  • Steps 1 to 3 were repeated 30 times.
  • 540 bp of fragment and 380 bp of fragment were amplified from primer sets of HL2/HL12 and HL2/HL6, respectively. They were gel-purified with GFXTM PCR DNA and Gel Band Purification kit (amersham pharmacia biotech) Each DNA was sequenced and compared to the lipase, showing that a clone encodes the internal part of the lipase.
  • Amplified DNA fragment was gel-purified with GFXTM PCR DNA and Gel Band Purification kit (Amersham Pharmacia Biotech) and ligated into a pT7Blue vector or pST BLue-1 AccepTor vector (Novagen) with ligation high (TOYOBO, Japan).
  • the ligation mixtures were transformed into E. coli JM109 or DH5 ⁇ .
  • the sequence of four plasmids of each gene was determined and their sequence were compared. The sequence of majority is defined as the right nucleotide sequence.
  • A Plasmid with gene from Talaromyces thermophilus and oligo 051200j1/051200j8 (SEQ ID NO: 11 and 18).
  • B Plasmid with gene from Talaromyces emersonii and oligo 051200j9/051200j16 (SEQ ID NO: 19 and 26).
  • C Plasmid with gene from Thermomyces Ibadanensis and oligo 051200j17/051200j24 (SEQ ID NO: 27 and 34).
  • PCR fragments were run and purified from a 1% agarose gel and cloned into pENI1960 (see above) using Gateway cloning as recommended by the supplier (Life Technologies) and transformed into E. coli DH10b (Life Technologies, Gaithersburg, Md.) and sequenced, thus creating pENI 2146 ( Talaromyces emersonii lipase gene), pENI2147 ( Thermomyces Ibadanensis lipase gene) and pENI2148 ( Talaromyces thermophilus lipase gene).
  • PCR-fragment was cloned into pENI1960 cut with Scal (in order to cleave in the ccdB gene) using Gateway cloning as recommended by the supplier (Life Technologies) and transformed into E. coli DH10b and sequenced, thus creating intron-less Talaromyces thermophilus lipase gene.
  • [0101] 2 051200j10 and 051200j13 (SEQ ID NO: 20 and 23).
  • [0102] 3 051200j12 and 051200j15 (SEQ ID NO: 22 and 25).
  • PCR-fragment was cloned into and cloned into pENI1960 cut Scal using Gateway cloning as recommended by the supplier (Life Technologies) and transformed into E. coli DH10b and sequenced, thus creating an intron-less Talaromyces emersonii lipase gene.
  • PCR-fragment was cloned into and cloned into pENI1960 cut Scal using Gateway cloning as recommended by supplier (life technologies) and transformed into E. coli DH10b and sequenced, thus creating intron-less Thermomyces lbadanensis lipase gene.
  • Plasmids containing DNA sequences encoding lipolytic enzymes are mixed in equimolar amounts.
  • the following components where mixed in a microtube:
  • the tube is set in a Perkin Elmer 2400 thermocycler.
  • the following PCR-program is run:(94° C., 5 minutes) 1 cycle:
  • the PCR-reaction is run on a 1.5% agarose gel.
  • a DNA-band of the specific expected size is cut out of the agarose gel and purified using JETsorb (from GENOMED Inc.).
  • the purified PCR-product is cloned into a TA-vector (from Invitrogen (the original TA cloning kit).
  • the ligated product is transformed into a standard Escherichia coli strain (DH5a).
  • the shuffled sequences can then be subcloned from the E. coli TA vector into the yeast vector pJSOO26 (WO 9928448) as a BamHI-Xbal fragment (see WO 97/07205), and e.g. screened for new shuffled sequences with improved properties, e.g. improved performance in detergents (see WO 97/07205).
  • PCR products of lipolytic enzyme genes are generated as in the previous example and pooled in equimolar amounts. The following mixture is generated in a suitable tube:
  • the mixture is set in a PE2400 thermocycler where the following program is run: 96° C., 5 minutes, 25° C. 5 minutes, 0.5 ml Klenow enzyme is added, 25° C. 60 minutes, 35° C. 90 minutes.
  • 10 ⁇ l PCR mixture (0.25 mM dNTP, 1 ⁇ l 10* Taq buffer (Perkin Elmer), 2.5 mM MgCl2, 0.5 ⁇ l Taq enzyme) is added to the 10 ⁇ l in the tube in the thermocycler. Then the following standard PCR-program is run: (94° C., 5 minutes) 1 cycle, (94° C 30 seconds, 45° C., 30 seconds, 72° C. 30 seconds) 25 cycles, 72° C. 7 minutes, 4° C. indefinite.
  • PCR products are run on a 1.5% agarose gel. A clear unbiased smear is seen. DNA between 400 and 800 bp is isolated from the gel.
  • Half of the purified PCR product is mixed in a tube with two specific primers (40 pmol) flanking the gene of interest, 0.25 mM dNTP, 2 ⁇ l 10* Taq buffer, 2.5 mM MgCl2. Then the following standard PCR-program is run: (94° C., 5 minutes) 1 cycle, (94° C. 30 seconds, 50° C., 30 seconds, 72° C. 30 seconds) 25 cycles, 72° 0 C. 7 minutes, 4° C. indefinite.
  • the PCR product is run on a 1.5% agarose gel. A band of the expected size is isolated. Additional PCR is run using specific primers (as mentioned above) in order to amplify the PCR-product before cloning.
  • PCR-product and the desired vector are cut with the appropriate restriction enzymes (BamHI/XhoI).
  • the vector and the PCR product are run on a 1.5% agarose gel, and purified from the gel.
  • the cut PCR-product and the cut vector are mixed in a ligase buffer with T4 DNA ligase (Promega). After overnight ligation at 16° C. the mixture is transformed into E. coli strain DH5a.
  • lipase genes with homology to the Thermomyces lanuginosus lipase gene were cloned. These genes were cloned as genomic DNA and were thus known to contain introns.
  • oligoes were used in standard PCR (as known to a person skilled in the art), thus creating PCR fragments covering each and every exon (coding sequence) in the gene. These PCR fragments were purified from a 1% agarose gel. The PCR fragments were assembled into a full length gene, in a second PCR using the DNA oligoes flanking the whole gene, as primers.
  • Talaromyces thermophilus 051200j1, 051200J2, 051200J3, 051200J4, 051200J5, 051200J6, 051200J7 and 051200J8 (SEQ ID NO: 11-18), thus creating pENI2178, when cloned into pENI1960.
  • Talaromyces emersonii 051200J9, 051200J10, 051200J11, 051200J12, 051200J13, 051200J14, 051200J15 and 051200J16 (SEQ ID NO: 19-26), thus creating pENI2159, when cloned into pENI1960.
  • Thermomyces ibadanensis 051200J17, 051200J18, 051200J19, 051200J20, 051200J21, 051200J22, 051200J23 and 051200J24 (SEQ ID NO: 27-34), thus creating pENI2160, when cloned into pENI1960.
  • Talaromyces byssochlamydoides 080201P1, 080201P2, 080201P3, 080201P4, 080201 P5, 080201P6, 080201P7 and 080201P8 (SEQ ID NO: 54-61), thus creating pENI2230 when cloned into pENI1960.
  • oligonucleotides are shown in FIG. 1: 1298-taka, 19670, 19672, 115120 and 050401P6 (SEQ ID NO: 62-65 and 68).
  • 050401P1 (SEQ ID NO: 66) hybridises to 5 ′ T. lanuginose lipase gene.
  • 030501 P1 (SEQ ID NO: 67) hybridises to 5′ of the other 4 lipase genes.
  • pENI2376 is a derivative of pENI1861(pat. PCT/DK02/00050).
  • the vector and PCR-fragment was purified from a 1% gel and ligated O/N.
  • the ligated DNA pool was transformed into electro-competent E. coli DH10B, thus creating a library of app. 700.000 independent clones.
  • This library can be screened for activity towards various substrates such as Lecithin, DGDG, triglycerides such as tributyrine, olive oil, PNP-valerate or PNP-palmitate at different conditions such as high pH, low pH, high temperature, in presences of detergent, in the presence of ions or in the absence of ions.
  • substrates such as Lecithin, DGDG, triglycerides such as tributyrine, olive oil, PNP-valerate or PNP-palmitate at different conditions such as high pH, low pH, high temperature, in presences of detergent, in the presence of ions or in the absence of ions.
  • DNA-oligoes 1298-taka: gcaagcgcgcgcaatacatggtgttttgatcat 19670: ccccatcctttaactatagcg 19672: ccacacttctcttccttcctc 115120: gctttgtgcagggtaaatc 050401P1: cggccgggccgcggaggccagggatccaccatgaggagctcccttgtgctg 030501P1: cggccgggccgcggaggccacaagtttgtacaaaaagcagg (hybridises to 5′
  • Lipolytic enzymes from Thermomyces ibadanensis and Talaromyces thermophilus were prepared as described above, purified and used for characterization
  • the specific lipase activity was determined by the LU method described in WO 0032758, and the amount of enzyme protein was determined from the optical density at 280 nm. The specific activity was found to be 3181 LU/mg for the Th. ibadanensis lipase and 1000 LU/mg for the Tal. thermophilus lipase.
  • the pH-activity relation was found by determining the lipase by the LU method at pH 5, 6, 7, 8, 9 and 10. Both enzymes were found to have the highest lipase activity at pH 10.
  • the Th. ibadanensis lipase showed a broad optimum with more than 50% of maximum activity in the pH range 6-10 whereas the Tal. thermophilus lipase showed a stronger activity drop at lower pH with less than 30% of maximum activity at pH 5-8.
  • thermostability was determined by differential scanning calorimetry (DSC) at pH 5 (50 mM acetate buffer), pH 7 (50 mM HEPES buffer) and pH 10 (50 mM glycine buffer) with a scan rate of 90° C./hr.
  • the temperature at the top of the denaturation peak (T d ) was found to be as follows: T d (° C.) pH T. ibadanesis T. thermophilus 5 74* 72* 7 72 75 10 64 69

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Detergent Compositions (AREA)
  • Cereal-Derived Products (AREA)

Abstract

The inventors have isolated novel genes with a high homology to the T. lanuginosus lipase gene and are thus well suited for use in gene shuffling. Accordingly, the invention provides a method of generating genetic diversity into lipolytic enzymes by family shuffling of two or more homologous genes which encode lipolytic enzymes. The DNA shuffling technique is used to create a library of shuffled genes, and this is expressed in a suitable expression system and the expressed proteins are screened for lipolytic enzyme activity. The expressed proteins may further be screened to identify lipolytic enzymes with improved properties. The invention also provides a polynucleotide comprising a nucleotide sequence encoding a lipolytic enzyme and a lipolytic enzyme (a polypeptide with lipolytic enzyme activity).

Description

    FIELD OF THE INVENTION
  • The present invention relates to a method of generating diversity into lipolytic enzymes by the use of the so-called family shuffling of homologous genes. The invention also relates to polynucleotides for use in the method, and to lipolytic enzymes encoded by the polynucleotides. [0001]
    • BACKGROUND OF THE INVENTION
  • The lipase of [0002] Thermomyces lanuginosus (also known as Humicola lanuginosa) is known to be useful for various industrial purposes such as detergents and baking (EP 258068, WO 9404035). Its amino acid and DNA sequences are shown in U.S. Pat. No. 5,869,438.
  • The prior art describes the modification of the amino acid sequence of the [0003] T. lanuginosus lipase to create variants with the aim of modifying the enzyme properties. Thus, U.S. Pat. No. 5,869,438, WO 9522615, WO 9704079 and WO 0032758 disclose the use of mutagenesis of the lipase gene to produce such variants. WO 0032758 also discloses the construction of variants with the backbone from T. lanuginosus lipase and C-terminal from Fusarium oxysporum phospholipase by PCR reaction.
  • Crameri et al, 1998, Nature, 391: 288-291 discloses DNA shuffling of a family of naturally occurring homologous genes from diverse species to create diversity into proteins. U.S. Pat. No. 6,159,687 discloses shuffling of genes encoding variants of the [0004] T. lanuginosus lipase. WO 9841623 discloses shuffling of heterologous polynucleotide sequences.
  • The following published sequences of lipolytic enzymes from Aspergillus have amino acid identities of 49-51% to the [0005] T. lanuginosus lipase: Lysophospholipase from A. foetidus (EMBL A93428, U.S. Pat. No. 6,140,094), lipase from A. tubingensis (EMBL A84589, WO 9845453), phospholipase A1 from A. oryzae (EMBL E16314, EP 575133, JP 10155493 A) and Lysophospholipase from A. niger (EMBL A90761, WO 98/31790).
  • R. Lattmann et al., Biocatalysis, 3 (1-2), 137-144 (1990) disclose an esterase from [0006] Talaromyces thermophilus. V. W. Ogundero, Mycologia, 72 (1), 118-126 (1980) describes the lipase activity of Talaromyces thermophilus. U.S. Pat. No. 4,275,011 and EP 258068 refer to a lipase from Thermomyces ibadanensis. B. A. Oso, Canadian Journal of Botany, 56: 1840-1843 (1978) describes the lipase activity of Talaromyces emersonii.
    • SUMMARY OF THE INVENTION
  • The inventors have isolated novel lipolytic enzyme genes with a high homology to the [0007] T. lanuginosus lipase gene and are thus well suited for use in gene shuffling. The novel genes are shown as SEQ ID NO: 3, 5, 7, 9 and 11. Identity tables for some protein and DNA sequences are shown below. The novel sequences are identified as follows:
  • Talthe1M: SEQ ID NO: 3 and 4 from [0008] Talaromyces thermophilus.
  • Theiba1M: SEQ ID NO: 5 and 6 from [0009] Thermomyces ibadanensis.
  • Taleme1M: SEQ ID NO: 7 and 8 from [0010] Talaromyces emersonii.
  • Talbys1M: SEQ ID NO: 9 and 10 from [0011] Talaromyces byssochiamydoides.
  • The following known sequences are included for comparison: [0012]
  • Thelan1M: Lipase from [0013] Thermomyces lanuginosus, SEQ ID NO: 1 and 2.
  • Asptub2M: EMBL A84589 Lipase from [0014] Aspergillus tubingensis.
  • Aspory3M: EMBL E16314 Phospholipase A1 from [0015] Aspergillus oryzae.
  • Aspnig2M: EMBL A90761 Lysophospholipase from [0016] Aspergillus niger.
  • The following is an identity table of the mature proteins: [0017]
    Thelan1 Talthe1 Theiba1 Taleme1 Talbys1 Asptub2 Aspory3 Aspnig2
    Thelan1M 100.0 88.1 78.1 61.9 57.4 50.6 50.4 49.1
    Talthe1M 88.1 100.0 78.8 61.5 59.2 48.7 47.8 48.0
    Theiba1M 78.1 78.8 100.0 61.8 58.0 49.4 50.4 48.0
    Taleme1M 61.9 61.5 61.8 100.0 83.1 54.8 56.1 53.7
    Talbys1M 57.4 59.2 58.0 83.1 100.0 50.9 54.9 49.1
    Asptub2M 50.6 48.7 49.4 54.8 50.9 100.0 55.9 93.7
    Aspory3M 50.4 47.8 50.4 56.1 54.9 55.9 100.0 53.7
    Aspnig2M 49.1 48.0 48.0 53.7 49.1 93.7 53.7 100.0
  • The following is an identity table of DNA sequences coding for the mature proteins (stop codons omitted): [0018]
    Thelan1 Talthe1 Theiba1 Taleme1 Talbys1 Asptub2 Aspory3 Aspnig2
    Thelan1M 100.0 86.0 79.3 62.0 58.4 57.0 55.6 56.2
    Talthe1M 86.0 100.0 79.1 62.6 60.0 57.8 55.7 57.1
    Theiba1M 79.3 79.1 100.0 63.5 60.4 56.6 57.8 55.6
    Taleme1M 62.0 62.6 63.5 100.0 84.1 58.2 58.4 58.7
    Talbys1M 58.4 60.0 60.4 84.1 100.0 57.5 56.5 56.8
    Asptub2M 57.0 57.8 56.6 58.2 57.5 100.0 58.7 91.7
    Aspory3M 55.6 55.7 57.8 58.4 56.5 58.7 100.0 56.5
    Aspnig2M 56.2 57.1 55.6 58.7 56.8 91.7 56.5 100.0
  • Accordingly, the invention provides a method of generating genetic diversity into lipolytic enzymes by family shuffling of two or more homologous genes which encode lipolytic enzymes. One gene encodes a lipolytic enzyme with at least 90% identity to the [0019] T. Ianuginosus lipase, and another gene encodes a lipolytic enzyme with 55-90% identity to the T. lanuginosus lipase. The DNA shuffling technique Is used to create a library of chimeric shuffled genes, and this is expressed in a suitable expression system and the expressed proteins are screened for lipolytic enzyme activity. The expressed proteins may further be screened to identify lipolytic enzymes with improved properties.
  • The invention also provides a polynucleotide comprising a nucleotide sequence encoding a lipolytic enzyme and a lipolytic enzyme (a polypeptide with lipolytic enzyme activity). [0020]
  • The polynucleotide may be a DNA sequence cloned into a plasmid present in [0021] E. coli deposit number DSM 14047, 14048, 14049, or 14051, the DNA sequence encoding a mature peptide shown in SEQ ID NO: 3, 5, 7 or 9 or one that can be derived therefrom by substitution, deletion, and/or insertion of one or more nucleotides. The polynucleotide may have at least 90% identity with the DNA sequence encoding a mature peptide shown in SEQ ID NO: 3, at least 80% identity with the DNA sequence encoding a mature peptide shown in SEQ ID NO: 5, at least 65% identity with the DNA sequence encoding a mature peptide shown in SEQ ID NO: 7, or at least 60% identity with the DNA sequence encoding a mature peptide shown in SEQ ID NO: 9. It may also be an allelic variant of the DNA sequence encoding a mature peptide shown in SEQ ID NO: 3, 5, 7 or 9; or it may hybridize under high stringency conditions with a complementary strand of the nucleic acid sequence encoding a mature peptide shown in SEQ ID NO: 3, 5, 7 or 9, or a subsequence thereof having at least 100 nucleotides.
  • The lipolytic enzyme may be encoded by a DNA sequence cloned into a plasmid present in [0022] E. coli deposit number DSM 14047 or 14049, or may have an amino acid sequence which is the mature peptide of SEQ ID NO: 6 or 10, or one that can be derived therefrom by substitution, deletion, and/or insertion of one or more amino acids. The lipolytic enzyme may have an amino acid sequence which has at least 80% identity with the mature peptide of SEQ ID NO: 6 or at least 60% identity with the mature peptide of SEQ ID NO: 10. The lipolytic enzyme may further be immunologically reactive with an antibody raised against the mature peptide of SEQ ID NO: 6 or 10 in purified form, be an allelic variant of the mature peptide of SEQ ID NO: 6 or 10; or be encoded by a nucleic acid sequence which hybridizes under high stringency conditions with a complementary strand of the nucleic acid sequence encoding a mature peptide shown in SEQ ID NO: 5 or 9, or a subsequence thereof having at least 100 nucleotides.
    •  BRIEF DESCRIPTION OF DRAWINGS
  • FIG. 1 shows a PCR scheme used in Example 7.[0023]
    • DETAILED DESCRIPTION OF THE INVENTION Genomic DNA Source
  • Lipolytic enzyme genes of the invention may be derived from strains of Talaromyces or Thermomyces, particularly [0024] Talaromyces thermophilus, Thermomyces ibadanensis, Talaromyces emersonii or Talaromyces byssochlamydoides, using probes designed on the basis of the DNA sequences in this specification.
  • Thus, genes and polypeptides shown in the sequence listing were isolated from the organisms indicated below. Strains of [0025] Escherichia coli containing the genes were deposited by the inventors under the terms of the Budapest Treaty with the DSMZ—Deutsche Sammlung von Microorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-38124 Braunschweig DE as follows:
    Gene and polypep- Clone de- Clone deposit
    Source organism tide sequences posit No. date
    Talaromyces thermophilus ATCC SEQ ID NO: 3 and DSM 14051 8 Feb.
    10518 4 2001
    Thermomyces ibadanensis CBS SEQ ID NO: 5 and DSM 14049 8 Feb.
    281.67 = ATCC 22716 6 2001
    Talaromyces emersonii UAMH SEQ ID NO: 7 and DSM 14048 8 Feb.
    5005 = NRRL 3221 = ATCC 16479 = 8 2001
    IMI 116815 = CBS 393.64
    Talaromyces byssochlamydoides SEQ ID NO: 9 and DSM 14047 8 Feb.
    CBS 413.71 = IMI 178524 = NRRL 10 2001
    3658
  • The above source organisms are freely available on commercial terms from the following strain collections: [0026]
  • ATCC (American Type Culture Collection), 10801 University Boulevard, Manassas, Va. 20110-2209, USA. [0027]
  • CBS (Centraalbureau voor Schimmelcultures), Uppsalalaan 8, 3584 CT Utrecht, The Netherlands. [0028]
  • UAMH (University of Alberta Mold Herbarium & Culture Collection), Devonian Botanic Garden, Edmonton, Alberta, Canada T6G 3GI. [0029]
  • IMI: International Mycological Institute, Bakeham Lane, Englefield Green, EGHAM, Surrey TW20 9TY, United Kingdom. [0030]
    • Polynucleotides
  • The polynucleotides to be used for recombination (shuffling) are two or more genes encoding lipolytic enzymes, including one with at least 90% identity and one with 55-90% identity to the [0031] T. lanuginosus lipase (SEQ ID NO: 2). The poloynucleotides differ in at least one nucleotide.
  • The starting material may include the mature part of two or more (e.g. three, four or five) of SEQ ID NO: 1, 3, 5, 7 and/or 9. It may also include genes encoding two or more (e.g. three, four or five) of variants of SEQ ID NO: 2, 4, 6, 8 or 10 obtained by deleting, substituting and/or inserting one or more amino acids and/or by attaching a peptide extension at the N- and/or C-terminal. Examples of variants of the [0032] T. lanuginosus lipase are described, e.g., in U.S. Pat. No. 5,869,438, WO 9522615, WO 9704079 and WO 0032758, and similar variants can be made by altering corresponding amino acids in the other sequences.
  • Any introns present in the genes may optionally be removed before the shuffling. [0033]
    • DNA Recombination (Shuffling)
  • Shuffling between two or more homologous input polynucleotides (starting-point polynucleotides) may involve fragmenting the polynucleotides and recombining the fragments, to obtain output polynucleotides (i.e. polynucleotides that have been subjected to a shuffling cycle) wherein a number of nucleotide fragments are exchanged in comparison to the input polynucleotides. [0034]
  • DNA recombination or shuffling may be a (partially) random process in which a library of chimeric genes is generated from two or more starting genes. A number of known formats can be used to carry out this shuffling or recombination process. [0035]
  • The process may involve random fragmentation of parental DNA followed by reassembly by PCR to new full length genes, e.g. as presented in U.S. Pat. No. 5,605,793, U.S. Pat. No. 5,811,238, U.S. Pat. No. 5,830,721, U.S. Pat. No. 6,117,679 . In-vitro recombination of genes may be carried out, e.g. as described in U.S. Pat. No. 6,159,687, WO98/41623, U.S. Pat. No. 6,159,688, U.S. Pat. No. 5,965,408, U.S. Pat. No. 6,153,510. The recombination process may take place in vivo in a living cell, e.g. as described in WO 97/07205 and WO 98/28416. [0036]
  • The parental DNA may be fragmented by DNA'se I treatment or by restriction endonuclease digests as descriobed by Kikuchi et al (2000a, Gene 236:159-167). Shuffling of two parents may be done by shuffling single stranded parental DNA of the two parents as described in Kikuchi et al (2000b, Gene 243:133-137). [0037]
  • A particular method of shuffling is to follow the methods described in Crameri et al, 1998, Nature, 391: 288-291 and Ness et al. Nature Biotechnology 17: 893-896. Another format would be the methods described in U.S. Pat. No. 6,159,687: example 1 and 2. [0038]
    • Properties of Lipolytic Enzyme
  • The lipolytic enzyme obtained by the invention is able to hydrolyze carboxylic ester bonds and is classified as EC 3.1.1 according to Enzyme Nomenclature 1992, Academic Press, Inc. It may particularly have activity as a lipase (triacylglycerol lipase) (EC 3.1.1.3), phospholipase A1 (EC 3.1.1.32), phospholipase A2 (EC 3.1.1.4), cholesterol esterase (EC 3.1.1.13) and/or galactolipase (EC 3.1.1.26). [0039]
  • The thermostability was evaluated by means of Differential Scanning Calorimetry (DSC). The denaturation peak (T[0040] d) when heated at 90 deg/hr at pH 5 is slightly above 75° C. for the lipolytic enzyme from T. ibadanensis, compared to slightly above 70° C. for the prior-art T. lanuginosus lipase. The lipolytic enzyme from T. ibadanensis has optimum activity at alkaline pH (similar to the T. lanuginosus lipase) and has an isoelectric point of about 4.3 (slightly lower than the T. lanuginosus lipase).
    • Homology and Alignment
  • The best alignment of the mature parts of SEQ ID NO: 2, 4, 6, 8 and 10 is achieved by inserting a gap of one amino acid between Q249 and P/G250 of SEQ ID NO: 2, 4 and 6. This alignment defines corresponding amino acids. [0041]
  • The degree of homology may be determined by means of computer programs known in the art, such as GAP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wis., USA 53711) (Needleman, S. B. and Wunsch, C. D., (1970), Journal of Molecular Biology, 48, 443-45), using GAP with the following settings for polypeptide sequence comparison: GAP creation penalty of 3.0 and GAP extension penalty of 0.1. [0042]
  • The determination of homology may also be made using Align from the fasta package version v20u6. Align is a Needleman-Wunsch alignment (i.e. global alignment), useful for both protein and DNA alignments. The default scoring matrices BLOSUM50 and the identity matrix are used for protein and DNA alignments respectively. The penalty for the first residue in a gap is −12 for proteins and −16 for DNA. While the penalty for additional residues in a gap is −2 for proteins and −4 for DNA. [0043]
  • The homologies discussed in this specification may correspond to at least 60% identity, in particular to at least 70% or at least 80% identity, e.g. at least 90% or at least 95% identity. [0044]
    • Use of Lipolytic Enzyme
  • Depending on the substrate specificity, the enzyme of the invention can be used, e.g., in filtration improvement, vegetable oil treatment, baking, detergents, or preparation of lysophospholipid. Thus, it may be used in known applications of lipolytic enzymes by analogy with the prior art, e.g.: [0045]
  • In the pulp and paper industry, to remove pitch or to remove ink from used paper. WO 9213130, WO 9207138, JP 2160984 A, EP 374700. [0046]
  • Baking. WO 94/04035, WO 00/32758. [0047]
  • Detergents. WO 97/04079, WO 97/07202, WO 97/41212, WO 98/08939 and WO 97/43375. [0048]
  • Leather industry. GB 2233665, EP 505920. [0049]
  • An enzyme with lipase activity may be used for fat hydrolysis and for modification of triglycerides and for production of mono- and diglycerides. [0050]
  • An enzyme with lipase activity may be used for interesterification of bulk fats, production of frying fats, shortenings and margarine components. [0051]
  • An enzyme with phospholipase activity (A1, A2) may be used for degumming of vegetable oils and for lysophospholipid production. [0052]
    • Improvement of Filtration
  • An enzyme with lysophospholipase activity can be used to improve the filterability of an aqueous solution or slurry of carbohydrate origin by treating it with the variant. This is particularly applicable to a solution or slurry containing a starch hydrolysate, especially a wheat starch hydrolysate since this tends to be difficult to filter and to give cloudy filtrates. The treatment can be done in analogy with EP 219,269 (CPC International). [0053]
    • Detergents
  • The lipolytic enzyme produced by the invention may be used as a detergent additive, e.g. at a concentration (expressed as pure enzyme protein) of 0.001-10 (e.g. 0.01-1) mg per gram of detergent or 0.001-100 (e.g. 0.01-10) mg per liter of wash liquor. [0054]
  • The detergent composition of the invention may for example be formulated as a hand or machine laundry detergent composition including a laundry additive composition suitable for pre-treatment of stained fabrics and a rinse added fabric softener composition, or be formulated as a detergent composition for use in general household hard surface cleaning operations. In a laundry detergent, the variant may be effective for the removal of fatty stains, for whiteness maintenance and for dingy cleanup. A laundry detergent composition may be formulated as described in WO 97/04079, WO 97/07202, WO 97/41212, PCT/DK WO 98/08939 and WO 97/43375. [0055]
  • The detergent composition of the invention may particularly be formulated for hand or machine dishwashing operations. e.g. as described in GB 2,247,025 (Unilever) or WO 99/01531 (Procter & Gamble). In a dishwashing composition, the variant may be effective for removal of greasy/oily stains, for prevention of the staining/discoloration of the dishware and plastic components of the dishwasher by highly colored components and the avoidance of lime soap deposits on the dishware. [0056]
  • The detergent composition of the invention may be in any convenient form, e.g., a bar, a tablet, a powder, a granule, a paste or a liquid. A liquid detergent may be aqueous, typically containing up to 70% water and 0-30% organic solvent, or non-aqueous. [0057]
  • The detergent composition comprises one or more surfactants, which may be non-ionic including semi-polar and/or anionic and/or cationic and/or zwitterionic. The surfactants are typically present at a level of from 0.1% to 60% by weight, e.g. 0.5-40%, such as 1-30%, typically 1.5-20%. [0058]
    • Dough and Baked Products
  • The lipolytic enzyme can be used in the preparation of dough and baked products made from dough, such as bread and cakes, e.g. to increase dough stability and dough handling properties, or to improve the elasticity of the bread or cake. Thus, it can be used in a process for making bread, comprising adding it to the ingredients of a dough, kneading the dough and baking the dough to make the bread. This can be done in analogy with U.S. Pat. No. 4,567,046 (Kyowa Hakko), JP-A 60-78529 (QP Corp.), JP-A 62-111629 (QP Corp.), JP-A 63-258528 (QP Corp.) or EP 426211 (Unilever). The lipolytic enzyme may be used together with an anti-staling amylase, particularly an endo-amylase such as a maltogenic amylase in analogy with WO 99/53769 (Novo Nordisk). Thus, the lipolytic enzyme may be incorporated in a flour composition such as a dough or a premix for dough. [0059]
    • MATERIALS AND METHODS Strains and Plasmids Plasmid pMT2188
  • The [0060] Aspergillus oryzae expression plasmid pCaHj 483 (WO 98/00529) consists of an expression cassette based on the Aspergillus niger neutral amylase II promoter fused to the Aspergillus nidulans triose phosphate isomerase non translated leader sequence (Pna2/tpi) and the A. niger amyloglycosidase terminator (Tamg). Also present on the plasmid is the Aspergillus selective marker amdS from A. nidulans enabling growth on acetamide as sole nitrogen source. These elements are cloned into the E. coli vector pUC19 (New England Biolabs). The ampicillin resistance marker enabling selection in E. coli of this plasmid was replaced with the URA3 marker of Saccharomyces cerevisiae that can complement a pyrF mutation in E. coli, the replacement was done in the following way:
  • The pUC19 origin of replication was PCR amplified from pCaHj483 with the primers 142779 (SEQ ID NO: 35) and 142780 (SEQ ID NO: 36). [0061]
  • Primer 142780 introduces a Bbul site in the PCR fragment. The Expand PCR system (Roche Molecular Biochemicals, Basel, Switserland) was used for the amplification following the manufacturers instructions for this and the subsequent PCR amplifications. [0062]
  • The URA3 gene was amplified from the general [0063] S. cerevisiae cloning vector pYES2 (Invitrogen corporation, Carlsbad, Calif., USA) using the primers 140288 (SEQ ID NO: 37) and 142778 (SEQ ID NO: 38).
  • Primer 140288 introduces an EcoRI site in the PCR fragment. The two PCR fragments were fused by mixing them and amplifying using the primers 142780 and 140288 in the splicing by overlap method (Horton et al (1989) Gene, 77, 61-68). [0064]
  • The resulting fragment was digested with EcoRI and BbuI and ligated to the largest fragment of pCaHj 483 digested with the same enzymes. The ligation mixture was used to transform the pyrF [0065] E. coli strain DB6507 (ATCC 35673) made competent by the method of Mandel and Higa (Mandel, M. and A. Higa (1970) J. Mol. Biol. 45, 154). Transformants were selected on solid M9 medium (Sambrook et. al (1989) Molecular cloning, a laboratory manual, 2. edition, Cold Spring Harbor Laboratory Press) supplemented with 1 g/l casaminoacids, 500 μg/l thiamine and 10 mg/l kanamycin.
  • A plasmid from a selected transformant was termed pCaHj 527. The Pna2/tpi promoter present on pCaHj527 was subjected to site directed mutagenises by a simple PCR approach. [0066]
  • Nucleotide 134-144 was altered from SEQ ID NO: 39 to SEQ ID NO: 40 using the mutagenic primer 141223 (SEQ ID NO: 41). [0067]
  • Nucleotide 423-436 was altered from SEQ ID NO: 42 to SEQ ID NO: 43 using the mutagenic primer 141222 (SEQ ID 44). [0068]
  • The resulting plasmid was termed pMT2188. [0069]
    • Plasmid pENI11861
  • Plasmid pENI1861 was made in order to have the state of the art Aspergillus promoter in the expression plasmid, as well as a number of unique restriction sites for cloning. [0070]
  • A PCR fragment (app. 620 bp) was made using pMT2188 (see above) as template and the primers 051199J1 (SEQ ID 45) and 1298TAKA (SEQ ID 46). [0071]
  • The fragment was cut BssHII and Bgl II, and cloned into pENI11849 which was also cut with BssHII and Bgl II. The cloning was verified by sequencing. Plasmid pENI1902 was made in order to have a promoter that works in both [0072] E. coli and Aspergillus. This was done by unique site elimination using the “Chameleon double stranded site-directed mutagenesis kit” as recommended by Stratagene®.
    • Plasmid pENI1861
  • Plasmid pENI1861 was used as template and the following primers with 5′ phosphorylation were used as selection primers: 177996 (SEQ ID 47), 135640 (SEQ ID 48) and 135638 (SEQ ID 49). [0073]
  • The 080399J19 primer (SEQ ID NO: 50) with 5′ phosphorylation was used as mutagenic primer to introduce a −35 and −10 promoter consensus sequence (from [0074] E. coli) in the Aspergillus expression promoter. Introduction of the mutations was verified by sequencing.
    • Plasmid pENI1960
  • Plasmid pENI1960 was made using the Gateway Vector™ conversion system (Lifetechnology® cat no. 11828-019) by cutting pENI1902 with BamHI, filling the DNA ends using Klenow fragment polymerase and nucleotides (thus making blunt ends) followed by ligation to reading frame A Gateway™ PCR fragment. The cloning in the correct orientation was confirmed by sequencing. [0075]
    • Media and Substrates
  • YPG: 4 g/L Yeast extract, 1 g/L KH2PO4, 0.5 g/L MgSO4-7aq, 5 g/L Glucose, pH 6.0. [0076]
    • EXAMPLES Example 1 Plasmids Harboring Lipolytic Enzyme Genes Genomic DNA Preparation
  • Strains of [0077] Thermomyces ibadanensis, Talaromyces emersonii, Talaromyces byssochlamydoides, and Talaromyces thermophilus were used as a genomic DNA supplier. Each strain was cultivated in 100 ml of YPG at appropriate temperature for several days. Mycelia was harvested and ground in liquid N2. It was suspended with 2 ml of 50 mM Tris-HCl (pH8.0) buffer including 100 mM NaCl, 25 mM EDTA, and 1% SDS and then 12 μl of proteinase K (25 mg/ml) was added. The suspension was incubated at 65° C. for 30-60min. Phenol extraction was done to remove proteins and DNA was precipitated by 0.7 volume of isopropanol. The precipitate was dissolved with sterilized water and RNase was added. After Phenol/isoamylalcohol extraction, DNA was precipitated by EtOH.
    • PCR Screening of Lipolytic Enzyme Genes
  • PCR reactions on each genomic DNA was done with HL 2 and HL12 (SEQ ID NO: 51 and 52) or HL2 and HL6 (SEQ ID NO: 51 and 53) designed based upon alignment lipases. [0078]
  • Reaction components (2.6 ng /μl of genomic DNA, 250 mM dNTP each, primer 250 nM each, 0.1 U/μl of Taq polymerase in 1× buffer (Roche Diagnostics, Japan)) were mixed and submitted for PCR under the following conditions. [0079]
    Step Temperature Time
    1 94° C.  1 min
    3 50° C.  1 min
    4 72° C.  2 min
    5 72° C. 10 min
    6  4° C. forever
  • Steps 1 to 3 were repeated 30 times. [0080]
  • 540 bp of fragment and 380 bp of fragment were amplified from primer sets of HL2/HL12 and HL2/HL6, respectively. They were gel-purified with GFX™ PCR DNA and Gel Band Purification kit (amersham pharmacia biotech) Each DNA was sequenced and compared to the lipase, showing that a clone encodes the internal part of the lipase. [0081]
    • Cloning of Lipase Genes
  • All lipase genes were cloned using LA PCR™ in vitro Cloning Kit (TaKaRa) according to the manufacturer's instructions. Thus, genomic DNA was cut with various restriction enzymes and each DNA was ligated with the appropriate cassette of the kit. Each ligation solution was applied to PCR with the primers of the one designed from internal sequence and a cassette primer of the kit. Amplified DAN fragment was sequenced. This step was repeated till ORF was determined. [0082]
  • The fidelity of LA-taq polymerase of the kit is not good so in order to get the right sequence whole gene was amplified by Expand high fidelity polymerase according to the manufacturer's instructions. [0083]
  • Amplified DNA fragment was gel-purified with GFX™ PCR DNA and Gel Band Purification kit (Amersham Pharmacia Biotech) and ligated into a pT7Blue vector or pST BLue-1 AccepTor vector (Novagen) with ligation high (TOYOBO, Japan). The ligation mixtures were transformed into [0084] E. coli JM109 or DH5α. The sequence of four plasmids of each gene was determined and their sequence were compared. The sequence of majority is defined as the right nucleotide sequence.
    • Example 2 Cloning of Lipase into Aspergillus Expression Vector
  • 3 different PCR reaction were run using PWO polymerase in the following reaction 94° C. 5 min, 30* (94° C. 30 sec., 50° C. 30 sec, 72° C. 2 min), 72° C. 5 min). In each case, the template was a plasmid harboring a lipolytic enzyme gene prepared as in Example 1, and the following primers were used: [0085]
  • A: Plasmid with gene from [0086] Talaromyces thermophilus and oligo 051200j1/051200j8 (SEQ ID NO: 11 and 18).
  • B: Plasmid with gene from [0087] Talaromyces emersonii and oligo 051200j9/051200j16 (SEQ ID NO: 19 and 26).
  • C: Plasmid with gene from [0088] Thermomyces Ibadanensis and oligo 051200j17/051200j24 (SEQ ID NO: 27 and 34).
  • The PCR fragments were run and purified from a 1% agarose gel and cloned into pENI1960 (see above) using Gateway cloning as recommended by the supplier (Life Technologies) and transformed into [0089] E. coli DH10b (Life Technologies, Gaithersburg, Md.) and sequenced, thus creating pENI 2146 (Talaromyces emersonii lipase gene), pENI2147 (Thermomyces Ibadanensis lipase gene) and pENI2148 (Talaromyces thermophilus lipase gene).
  • These were transformed into Jal250 (described in WO 00/39322) and lipase activity identified as mentioned in pat WO 00/24883. [0090]
    • Example 3 Construction of Intron-Less Lipase Genes Removal of Introns from Talaromyces Thermophilus Lipase Gene
  • 4 PCR reactions were run using PWO polymerase and pENI2148 as template (94° C. 5 min, 30* (94° C. 30 sec, 50° C. 30 sec, 72° C. 1 min), 72° C. 5 min) and the following oligoes: [0091]
  • 1: 051200j1 and 051200j3 (SEQ ID NO: 11 and 13) [0092]
  • 2: 051200j2 and 051200j5 (SEQ ID NO: 12 and 15) [0093]
  • 3: 051200j4 and 051200j7 (SEQ ID NO: 14 and 17) [0094]
  • 4: 051200j6 and 051200j8 (SEQ ID NO: 16 and 18) [0095]
  • The specific bands were run and purified from a 1.5% agarose gel. Equal amounts of PCR fragments were mixed along with PWO polymerase, buffer, dNTP, oligo 051200j1 and 051200j8 (SEQ ID NO: 11 and 18, total of 50 μl, as recommended by the supplier Boehringer Mannheim) and a second PCR was run (94° C. 5 min, 30* (94° C. 30 sec., 50° C. 30 sec, 72° C. 2 min), 72° C. 5 min). [0096]
  • The correct band size was checked on a 1.5% agarose gel ( app. 900 bp) and the rest of the PCR-fragment was purified using Biorad spin columns (cat no.732-6225). [0097]
  • The PCR-fragment was cloned into pENI1960 cut with Scal (in order to cleave in the ccdB gene) using Gateway cloning as recommended by the supplier (Life Technologies) and transformed into [0098] E. coli DH10b and sequenced, thus creating intron-less Talaromyces thermophilus lipase gene.
    • Removal of Introns from Talaromyces Emersonii Lipase Gene
  • 4 PCR reactions were run using PWO polymerase and pENI2146 as template (94° C. 5 min, 30* (94° C. 30 sec, 50° C. 30 sec, 72° C. 1 min), 72° C. 5 min) and the following oligoes: [0099]
  • 1: 051200j9 and 051200j11 (SEQ ID NO: 19 and 21). [0100]
  • 2: 051200j10 and 051200j13 (SEQ ID NO: 20 and 23). [0101]
  • 3: 051200j12 and 051200j15 (SEQ ID NO: 22 and 25). [0102]
  • 4: 051200j14 and 051200j16 (SEQ ID NO: 24 and 26). [0103]
  • The specific bands were run and purified from a 1.5% agarose gel. Equal amounts of PCR fragments were mixed along with PWO polymerase, buffer, dNTP, oligo 051200j9 and 051200j16 (SEQ ID NO: 19 and 26, total of 50 μl, as recommended by the supplier) and a second PCR was run (94° C. 5 min, 30* (94° C. 30 sec, 50° C. 30 sec, 72° C. 2 min), 72° C. 5 min). [0104]
  • The correct band size was checked on a 1.5% agarose gel (app. 900 bp) and the rest of the PCR-fragment was purified using Biorad spin columns. [0105]
  • The PCR-fragment was cloned into and cloned into pENI1960 cut Scal using Gateway cloning as recommended by the supplier (Life Technologies) and transformed into [0106] E. coli DH10b and sequenced, thus creating an intron-less Talaromyces emersonii lipase gene.
    • Removal of Introns from Thermomyces lbadanensis Lipase Gene
  • 4 PCR reactions were run using PWO polymerase and pENI12147 as template (94° C. 5 min, 30* (94° C. 30 sec, 50° C. 30 sec, 72° C. 1 min), 72° C. 5 min) and the following oligoes: [0107]
  • 1: 051200j17 and 051200j19 (SEQ ID NO: 27 and 29). [0108]
  • 2: 051200j18 and 051200j21 (SEQ ID NO: 28 and 31). [0109]
  • 3: 051200j20 and 051200j23 (SEQ ID NO: 30 and 33). [0110]
  • 4: 051200j22 and 051200j24 (SEQ ID NO: 32 and 34). [0111]
  • The specific bands were run and purified from a 1.5% agarose gel. Equal amounts of PCR fragments were mixed along with PWO polymerase, buffer, dNTP, oligo 051200j17 and 051200j24 (SEQ ID NO: 27 and 34, total of 50 μl, as recommended by the supplier) and a second PCR was run (94° C. 5 min, 30* (94° C. 30 sec., 50° C. 30 sec, 72° C. 2 min), 72° C. 5 min). [0112]
  • The correct band size was checked on a 1.5% agarose gel ( app. 900 bp) and the rest of the PCR-fragment was purified using Biorad spin columns. [0113]
  • The PCR-fragment was cloned into and cloned into pENI1960 cut Scal using Gateway cloning as recommended by supplier (life technologies) and transformed into [0114] E. coli DH10b and sequenced, thus creating intron-less Thermomyces lbadanensis lipase gene.
    • Example 4 Shuffling of Lipolytic Enzyme Genes
  • Plasmids containing DNA sequences encoding lipolytic enzymes are mixed in equimolar amounts. The following components where mixed in a microtube: [0115]
  • 2 μl plasmid mixture (0.15 μg/μl), specific primers flanking the gene (1 pmol/μ), 2 μl 2.5 mM dNTP, 2.5 mM MgCl2, 2 μl 10* taq buffer (Perkin Elmer), 0.5 μl taq enzyme in a total volume of 20 μl. [0116]
  • The tube is set in a Perkin Elmer 2400 thermocycler. The following PCR-program is run:(94° C., 5 minutes) 1 cycle: [0117]
  • (94° C., 30 seconds, 70° C., 0 seconds) 99 cycles(72° C., 2 minutes, 4° C. indefinite) 1 cycle. [0118]
  • The PCR-reaction is run on a 1.5% agarose gel. A DNA-band of the specific expected size is cut out of the agarose gel and purified using JETsorb (from GENOMED Inc.). The purified PCR-product is cloned into a TA-vector (from Invitrogen (the original TA cloning kit). The ligated product is transformed into a standard Escherichia coli strain (DH5a). [0119]
  • The shuffled sequences can then be subcloned from the [0120] E. coli TA vector into the yeast vector pJSOO26 (WO 9928448) as a BamHI-Xbal fragment (see WO 97/07205), and e.g. screened for new shuffled sequences with improved properties, e.g. improved performance in detergents (see WO 97/07205).
    • Example 5 Shuffling of Lipolytic Enzyme Genes
  • PCR products of lipolytic enzyme genes are generated as in the previous example and pooled in equimolar amounts. The following mixture is generated in a suitable tube: [0121]
  • 1 μl PCR mixture (0.1 μg), decamer random primer (300 pmol), 2 μl 10* Klenow buffer (Promega), 0.25 mM dNTP, 2.5 mM MgCl2 in a total volume of 20 μl. [0122]
  • The mixture is set in a PE2400 thermocycler where the following program is run: 96° C., 5 minutes, 25° C. 5 minutes, 0.5 ml Klenow enzyme is added, 25° C. 60 minutes, 35° C. 90 minutes. [0123]
  • This procedure generates a high number of small DNA polymers originating from all parts of the gene. [0124]
  • 10 μl is taken out for test on agarose gel. [0125]
  • 10 μl PCR mixture (0.25 mM dNTP, 1 μl 10* Taq buffer (Perkin Elmer), 2.5 mM MgCl2, 0.5 μl Taq enzyme) is added to the 10 μl in the tube in the thermocycler. Then the following standard PCR-program is run: (94° C., 5 minutes) 1 cycle, (94° C 30 seconds, 45° C., 30 seconds, 72° C. 30 seconds) 25 cycles, 72° C. 7 minutes, 4° C. indefinite. [0126]
  • The PCR products are run on a 1.5% agarose gel. A clear unbiased smear is seen. DNA between 400 and 800 bp is isolated from the gel. [0127]
  • Half of the purified PCR product is mixed in a tube with two specific primers (40 pmol) flanking the gene of interest, 0.25 mM dNTP, 2 μl 10* Taq buffer, 2.5 mM MgCl2. Then the following standard PCR-program is run: (94° C., 5 minutes) 1 cycle, (94° C. 30 seconds, 50° C., 30 seconds, 72° C. 30 seconds) 25 cycles, 72°[0128] 0 C. 7 minutes, 4° C. indefinite.
  • The PCR product is run on a 1.5% agarose gel. A band of the expected size is isolated. Additional PCR is run using specific primers (as mentioned above) in order to amplify the PCR-product before cloning. [0129]
  • The PCR-product and the desired vector are cut with the appropriate restriction enzymes (BamHI/XhoI). The vector and the PCR product are run on a 1.5% agarose gel, and purified from the gel. [0130]
  • The cut PCR-product and the cut vector are mixed in a ligase buffer with T4 DNA ligase (Promega). After overnight ligation at 16° C. the mixture is transformed into [0131] E. coli strain DH5a.
    • Example 6 Creation of Intron-Less Lipase Genes
  • A number of lipase genes with homology to the [0132] Thermomyces lanuginosus lipase gene were cloned. These genes were cloned as genomic DNA and were thus known to contain introns.
  • The intention was to shuffle these genes in order to obtain chimeric genes. In order to obtain the highest possible quality of library, the introns had to be removed. This was done by creating DNA oligo's matching each flank of an exon as well as having a DNA sequence, which is homologous to the next neighbour exon. [0133]
  • These oligoes were used in standard PCR (as known to a person skilled in the art), thus creating PCR fragments covering each and every exon (coding sequence) in the gene. These PCR fragments were purified from a 1% agarose gel. The PCR fragments were assembled into a full length gene, in a second PCR using the DNA oligoes flanking the whole gene, as primers. [0134]
  • The PCR fragment-containing the full length intron-less gene encoding the lipase was cloned into pENI 1960 as described in pat. appl. PCT/DK02/00050. [0135]
  • The following primers were used to assemble each intron-less gene: [0136]
  • [0137] Talaromyces thermophilus: 051200j1, 051200J2, 051200J3, 051200J4, 051200J5, 051200J6, 051200J7 and 051200J8 (SEQ ID NO: 11-18), thus creating pENI2178, when cloned into pENI1960.
  • [0138] Talaromyces emersonii: 051200J9, 051200J10, 051200J11, 051200J12, 051200J13, 051200J14, 051200J15 and 051200J16 (SEQ ID NO: 19-26), thus creating pENI2159, when cloned into pENI1960.
  • [0139] Thermomyces ibadanensis: 051200J17, 051200J18, 051200J19, 051200J20, 051200J21, 051200J22, 051200J23 and 051200J24 (SEQ ID NO: 27-34), thus creating pENI2160, when cloned into pENI1960.
  • [0140] Talaromyces byssochlamydoides: 080201P1, 080201P2, 080201P3, 080201P4, 080201 P5, 080201P6, 080201P7 and 080201P8 (SEQ ID NO: 54-61), thus creating pENI2230 when cloned into pENI1960.
    • Example 7 Shuffling of the Intron-Less Lipase Genes
  • A method using dUTP and uracil-DNA glycosylase was employed in order to make DNA fragments in sufficient quantities for DNA shuffling. The 3 genes [0141] T. lanuginosus, T. thermophilus and T. ibadanensis are quite homologous to each other (thus named Group A) as are T. emersonii and T. byssochlamydoides (named Group B). Thus in order to improve recombination between the two groups the following PCR scheme (see FIG. 1) was employed, using the following templates: pENI2178, pENI2159, pENI2160, pENI2230, and the T. lanuginosus gene cloned into pENI1902 (cut BamHI and SacII) (pat. PCT/DK02/00050).
  • The following oligonucleotides are shown in FIG. 1: 1298-taka, 19670, 19672, 115120 and 050401P6 (SEQ ID NO: 62-65 and 68). 050401P1 (SEQ ID NO: 66) hybridises to 5[0142] ′ T. lanuginose lipase gene. 030501 P1 (SEQ ID NO: 67) hybridises to 5′ of the other 4 lipase genes.
  • The final PCR fragment was cut first with BstEII and then with Sfil, as was the vector pENI2376. pENI2376 is a derivative of pENI1861(pat. PCT/DK02/00050). [0143]
  • The vector and PCR-fragment was purified from a 1% gel and ligated O/N. The ligated DNA pool was transformed into electro-competent [0144] E. coli DH10B, thus creating a library of app. 700.000 independent clones.
  • This library can be screened for activity towards various substrates such as Lecithin, DGDG, triglycerides such as tributyrine, olive oil, PNP-valerate or PNP-palmitate at different conditions such as high pH, low pH, high temperature, in presences of detergent, in the presence of ions or in the absence of ions. [0145]
  • This can be done in order to find, e.g., a thermo-stable lipase, a detergent phospholipase, a detergent lipase with first-wash performance, and no activity at neutral pH and so forth. [0146]
    DNA-oligoes:
    1298-taka: gcaagcgcgcgcaatacatggtgttttgatcat
    19670: ccccatcctttaactatagcg
    19672: ccacacttctcttccttcctc
    115120: gctttgtgcagggtaaatc
    050401P1: cggccgggccgcggaggccagggatccaccatgaggagctcccttgtgctg
    030501P1: cggccgggccgcggaggccacaagtttgtacaaaaaagcagg
    (hybridises to 5′ of the other 4 lipase genes)
    050401P6: cggccgggtcaccccccatcctttaactatagcg
    • Example 8 Characterization of Lipolytic Enzymes
  • Lipolytic enzymes from [0147] Thermomyces ibadanensis and Talaromyces thermophilus were prepared as described above, purified and used for characterization
  • The specific lipase activity was determined by the LU method described in WO 0032758, and the amount of enzyme protein was determined from the optical density at 280 nm. The specific activity was found to be 3181 LU/mg for the [0148] Th. ibadanensis lipase and 1000 LU/mg for the Tal. thermophilus lipase.
  • The pH-activity relation was found by determining the lipase by the LU method at pH 5, 6, 7, 8, 9 and 10. Both enzymes were found to have the highest lipase activity at pH 10. The [0149] Th. ibadanensis lipase showed a broad optimum with more than 50% of maximum activity in the pH range 6-10 whereas the Tal. thermophilus lipase showed a stronger activity drop at lower pH with less than 30% of maximum activity at pH 5-8.
  • The thermostability was determined by differential scanning calorimetry (DSC) at pH 5 (50 mM acetate buffer), pH 7 (50 mM HEPES buffer) and pH 10 (50 mM glycine buffer) with a scan rate of 90° C./hr. The temperature at the top of the denaturation peak (T[0150] d) was found to be as follows:
    Td (° C.)
    pH T. ibadanesis T. thermophilus
    5  74*  72*
    7 72 75
    10 64 69
    • Example 9 Lysophospholipase Activity
  • Purified lipolytic enzymes from [0151] T. ibadanensis and T. thermos were tested by incubating with lysolecithin as substrate at pH 5 and 7, and the extent of reaction was followed by use of NEFA kit.
  • The results were that the enzyme from [0152] T. ibadanensis showed high lysophospholipase activity at pH 5 and some activity at pH 7. The enzyme from T. thermos showed a slight activity.
  • 1 53 1 918 DNA Thermomyces lanuginosus CDS (1)..(873) sig_peptide (1)..(66) mat_peptide (67)..() 1 atg agg agc tcc ctt gtg ctg ttc ttt gtc tct gcg tgg acg gcc ttg 48 Met Arg Ser Ser Leu Val Leu Phe Phe Val Ser Ala Trp Thr Ala Leu -20 -15 -10 gcc agt cct att cgt cga gag gtc tcg cag gat ctg ttt aac cag ttc 96 Ala Ser Pro Ile Arg Arg Glu Val Ser Gln Asp Leu Phe Asn Gln Phe -5 -1 1 5 10 aat ctc ttt gca cag tat tct gca gcc gca tac tgc gga aaa aac aat 144 Asn Leu Phe Ala Gln Tyr Ser Ala Ala Ala Tyr Cys Gly Lys Asn Asn 15 20 25 gat gcc cca gct ggt aca aac att acg tgc acg gga aat gcc tgc ccc 192 Asp Ala Pro Ala Gly Thr Asn Ile Thr Cys Thr Gly Asn Ala Cys Pro 30 35 40 gag gta gag aag gcg gat gca acg ttt ctc tac tcg ttt gaa gac tct 240 Glu Val Glu Lys Ala Asp Ala Thr Phe Leu Tyr Ser Phe Glu Asp Ser 45 50 55 gga gtg ggc gat gtc acc ggc ttc ctt gct ctc gac aac acg aac aaa 288 Gly Val Gly Asp Val Thr Gly Phe Leu Ala Leu Asp Asn Thr Asn Lys 60 65 70 ttg atc gtc ctc tct ttc cgt ggc tct cgt tcc ata gag aac tgg atc 336 Leu Ile Val Leu Ser Phe Arg Gly Ser Arg Ser Ile Glu Asn Trp Ile 75 80 85 90 ggg aat ctt aac ttc gac ttg aaa gaa ata aat gac att tgc tcc ggc 384 Gly Asn Leu Asn Phe Asp Leu Lys Glu Ile Asn Asp Ile Cys Ser Gly 95 100 105 tgc agg gga cat gac ggc ttc act tcg tcc tgg agg tct gta gcc gat 432 Cys Arg Gly His Asp Gly Phe Thr Ser Ser Trp Arg Ser Val Ala Asp 110 115 120 acg tta agg cag aag gtg gag gat gct gtg agg gag cat ccc gac tat 480 Thr Leu Arg Gln Lys Val Glu Asp Ala Val Arg Glu His Pro Asp Tyr 125 130 135 cgc gtg gtg ttt acc gga cat agc ttg ggt ggt gca ttg gca act gtt 528 Arg Val Val Phe Thr Gly His Ser Leu Gly Gly Ala Leu Ala Thr Val 140 145 150 gcc gga gca gac ctg cgt gga aat ggg tat gat atc gac gtg ttt tca 576 Ala Gly Ala Asp Leu Arg Gly Asn Gly Tyr Asp Ile Asp Val Phe Ser 155 160 165 170 tat ggc gcc ccc cga gtc gga aac agg gct ttt gca gaa ttc ctg acc 624 Tyr Gly Ala Pro Arg Val Gly Asn Arg Ala Phe Ala Glu Phe Leu Thr 175 180 185 gta cag acc ggc gga aca ctc tac cgc att acc cac acc aat gat att 672 Val Gln Thr Gly Gly Thr Leu Tyr Arg Ile Thr His Thr Asn Asp Ile 190 195 200 gtc cct aga ctc ccg ccg cgc gaa ttc ggt tac agc cat tct agc cca 720 Val Pro Arg Leu Pro Pro Arg Glu Phe Gly Tyr Ser His Ser Ser Pro 205 210 215 gag tac tgg atc aaa tct gga acc ctt gtc ccc gtc acc cga aac gat 768 Glu Tyr Trp Ile Lys Ser Gly Thr Leu Val Pro Val Thr Arg Asn Asp 220 225 230 atc gtg aag ata gaa ggc atc gat gcc acc ggc ggc aat aac cag cct 816 Ile Val Lys Ile Glu Gly Ile Asp Ala Thr Gly Gly Asn Asn Gln Pro 235 240 245 250 aac att ccg gat atc cct gcg cac cta tgg tac ttc ggg tta att ggg 864 Asn Ile Pro Asp Ile Pro Ala His Leu Trp Tyr Phe Gly Leu Ile Gly 255 260 265 aca tgt ctt tagtggccgg cgcggctggg tccgactcta gcgagctcga gatct 918 Thr Cys Leu 2 291 PRT Thermomyces lanuginosus 2 Met Arg Ser Ser Leu Val Leu Phe Phe Val Ser Ala Trp Thr Ala Leu -20 -15 -10 Ala Ser Pro Ile Arg Arg Glu Val Ser Gln Asp Leu Phe Asn Gln Phe -5 -1 1 5 10 Asn Leu Phe Ala Gln Tyr Ser Ala Ala Ala Tyr Cys Gly Lys Asn Asn 15 20 25 Asp Ala Pro Ala Gly Thr Asn Ile Thr Cys Thr Gly Asn Ala Cys Pro 30 35 40 Glu Val Glu Lys Ala Asp Ala Thr Phe Leu Tyr Ser Phe Glu Asp Ser 45 50 55 Gly Val Gly Asp Val Thr Gly Phe Leu Ala Leu Asp Asn Thr Asn Lys 60 65 70 Leu Ile Val Leu Ser Phe Arg Gly Ser Arg Ser Ile Glu Asn Trp Ile 75 80 85 90 Gly Asn Leu Asn Phe Asp Leu Lys Glu Ile Asn Asp Ile Cys Ser Gly 95 100 105 Cys Arg Gly His Asp Gly Phe Thr Ser Ser Trp Arg Ser Val Ala Asp 110 115 120 Thr Leu Arg Gln Lys Val Glu Asp Ala Val Arg Glu His Pro Asp Tyr 125 130 135 Arg Val Val Phe Thr Gly His Ser Leu Gly Gly Ala Leu Ala Thr Val 140 145 150 Ala Gly Ala Asp Leu Arg Gly Asn Gly Tyr Asp Ile Asp Val Phe Ser 155 160 165 170 Tyr Gly Ala Pro Arg Val Gly Asn Arg Ala Phe Ala Glu Phe Leu Thr 175 180 185 Val Gln Thr Gly Gly Thr Leu Tyr Arg Ile Thr His Thr Asn Asp Ile 190 195 200 Val Pro Arg Leu Pro Pro Arg Glu Phe Gly Tyr Ser His Ser Ser Pro 205 210 215 Glu Tyr Trp Ile Lys Ser Gly Thr Leu Val Pro Val Thr Arg Asn Asp 220 225 230 Ile Val Lys Ile Glu Gly Ile Asp Ala Thr Gly Gly Asn Asn Gln Pro 235 240 245 250 Asn Ile Pro Asp Ile Pro Ala His Leu Trp Tyr Phe Gly Leu Ile Gly 255 260 265 Thr Cys Leu 3 1083 DNA Talaromyces thermophilus CDS (1)..(67) mat_peptide (67)..() CDS (139)..(307) CDS (370)..(703) CDS (778)..(1080) 3 atg agg agc tcg ctc gtg ctg ttc ttc gtt tct gcg tgg acg gcc ttg 48 Met Arg Ser Ser Leu Val Leu Phe Phe Val Ser Ala Trp Thr Ala Leu -20 -15 -10 gcc agt cct gtc cga cga g gtatgtaaat cacggggtat acttttcatg 97 Ala Ser Pro Val Arg Arg -5 -1 cattgcatgt cgaacctgct gtactaagat tgcgcgcaca g ag gtc tcg cag gat 152 Glu Val Ser Gln Asp 5 ctg ttt gac cag ttc aac ctc ttt gcg cag tac tcg gcg gcc gca tac 200 Leu Phe Asp Gln Phe Asn Leu Phe Ala Gln Tyr Ser Ala Ala Ala Tyr 10 15 20 tgc gcg aag aac aac gat gcc ccg gca ggt ggg aac gta acg tgc agg 248 Cys Ala Lys Asn Asn Asp Ala Pro Ala Gly Gly Asn Val Thr Cys Arg 25 30 35 gga agt att tgc ccc gag gta gag aag gcg gat gca acg ttt ctc tac 296 Gly Ser Ile Cys Pro Glu Val Glu Lys Ala Asp Ala Thr Phe Leu Tyr 40 45 50 tcg ttt gag ga gtaggtgtca acaagagtac aggcacccgt agtagaaata 347 Ser Phe Glu Asp 55 gcagactaac tgggaaatgt ag t tct gga gtt ggc gat gtc acc ggg ttc 397 Ser Gly Val Gly Asp Val Thr Gly Phe 60 65 ctt gct ctc gac aac acg aac aga ctg atc gtc ctc tct ttc cgc ggc 445 Leu Ala Leu Asp Asn Thr Asn Arg Leu Ile Val Leu Ser Phe Arg Gly 70 75 80 tct cgt tcc ctg gaa aac tgg atc ggg aat atc aac ttg gac ttg aaa 493 Ser Arg Ser Leu Glu Asn Trp Ile Gly Asn Ile Asn Leu Asp Leu Lys 85 90 95 gga att gac gac atc tgc tct ggc tgc aag gga cat gac ggc ttc act 541 Gly Ile Asp Asp Ile Cys Ser Gly Cys Lys Gly His Asp Gly Phe Thr 100 105 110 tcc tcc tgg agg tcc gtt gcc aat acc ttg act cag caa gtg cag aat 589 Ser Ser Trp Arg Ser Val Ala Asn Thr Leu Thr Gln Gln Val Gln Asn 115 120 125 130 gct gtg agg gag cat ccc gac tac cgc gtc gtc ttc act ggg cac agc 637 Ala Val Arg Glu His Pro Asp Tyr Arg Val Val Phe Thr Gly His Ser 135 140 145 ttg ggt ggt gca ttg gca act gtg gcc ggg gca tct ctg cgt gga aat 685 Leu Gly Gly Ala Leu Ala Thr Val Ala Gly Ala Ser Leu Arg Gly Asn 150 155 160 ggg tac gat ata gat gtg gtatgtagga aaaatgatcc ccgtggagcg 733 Gly Tyr Asp Ile Asp Val 165 gtcatgtgga aatgtgcagg ggtgtctaat acacagacca acag ttc tca tat ggc 789 Phe Ser Tyr Gly 170 gct ccc cgc gtc gga aac agg gct ttt gcg gaa ttc ctg acc gca cag 837 Ala Pro Arg Val Gly Asn Arg Ala Phe Ala Glu Phe Leu Thr Ala Gln 175 180 185 acc ggc ggc acc ttg tac cgc atc acc cac acc aat gat att gtc ccc 885 Thr Gly Gly Thr Leu Tyr Arg Ile Thr His Thr Asn Asp Ile Val Pro 190 195 200 aga ctc ccg cca cgc gaa ttg ggt tac agc cat tct agc cca gag tat 933 Arg Leu Pro Pro Arg Glu Leu Gly Tyr Ser His Ser Ser Pro Glu Tyr 205 210 215 220 tgg atc acg tct gga acc ctc gtc cca gtg acc aag aac gat atc gtc 981 Trp Ile Thr Ser Gly Thr Leu Val Pro Val Thr Lys Asn Asp Ile Val 225 230 235 aag gtg gag ggc atc gat tcc acc gat gga aac aac cag cca aat acc 1029 Lys Val Glu Gly Ile Asp Ser Thr Asp Gly Asn Asn Gln Pro Asn Thr 240 245 250 ccg gac att gct gcg cac cta tgg tac ttc ggg tca atg gcg acg tgt 1077 Pro Asp Ile Ala Ala His Leu Trp Tyr Phe Gly Ser Met Ala Thr Cys 255 260 265 ttg taa 1083 Leu 4 291 PRT Talaromyces thermophilus 4 Met Arg Ser Ser Leu Val Leu Phe Phe Val Ser Ala Trp Thr Ala Leu -20 -15 -10 Ala Ser Pro Val Arg Arg Glu Val Ser Gln Asp Leu Phe Asp Gln Phe -5 -1 1 5 10 Asn Leu Phe Ala Gln Tyr Ser Ala Ala Ala Tyr Cys Ala Lys Asn Asn 15 20 25 Asp Ala Pro Ala Gly Gly Asn Val Thr Cys Arg Gly Ser Ile Cys Pro 30 35 40 Glu Val Glu Lys Ala Asp Ala Thr Phe Leu Tyr Ser Phe Glu Asp Ser 45 50 55 Gly Val Gly Asp Val Thr Gly Phe Leu Ala Leu Asp Asn Thr Asn Arg 60 65 70 Leu Ile Val Leu Ser Phe Arg Gly Ser Arg Ser Leu Glu Asn Trp Ile 75 80 85 90 Gly Asn Ile Asn Leu Asp Leu Lys Gly Ile Asp Asp Ile Cys Ser Gly 95 100 105 Cys Lys Gly His Asp Gly Phe Thr Ser Ser Trp Arg Ser Val Ala Asn 110 115 120 Thr Leu Thr Gln Gln Val Gln Asn Ala Val Arg Glu His Pro Asp Tyr 125 130 135 Arg Val Val Phe Thr Gly His Ser Leu Gly Gly Ala Leu Ala Thr Val 140 145 150 Ala Gly Ala Ser Leu Arg Gly Asn Gly Tyr Asp Ile Asp Val Phe Ser 155 160 165 170 Tyr Gly Ala Pro Arg Val Gly Asn Arg Ala Phe Ala Glu Phe Leu Thr 175 180 185 Ala Gln Thr Gly Gly Thr Leu Tyr Arg Ile Thr His Thr Asn Asp Ile 190 195 200 Val Pro Arg Leu Pro Pro Arg Glu Leu Gly Tyr Ser His Ser Ser Pro 205 210 215 Glu Tyr Trp Ile Thr Ser Gly Thr Leu Val Pro Val Thr Lys Asn Asp 220 225 230 Ile Val Lys Val Glu Gly Ile Asp Ser Thr Asp Gly Asn Asn Gln Pro 235 240 245 250 Asn Thr Pro Asp Ile Ala Ala His Leu Trp Tyr Phe Gly Ser Met Ala 255 260 265 Thr Cys Leu 5 1070 DNA Thermomyces ibadanensis CDS (1)..(67) mat_peptide (67)..() CDS (128)..(296) CDS (357)..(690) CDS (765)..(1067) 5 atg cgg agc tcc ctc gtg ctg ttc ttc ctc tct gcg tgg acg gcc ttg 48 Met Arg Ser Ser Leu Val Leu Phe Phe Leu Ser Ala Trp Thr Ala Leu -20 -15 -10 gcg cgg cct gtt cga cga g gtatgtagca agggacacta ttacatgttg 97 Ala Arg Pro Val Arg Arg -5 -1 accttggtga ttctaagact gcatgcgcag cg gtt ccg caa gat ctg ctc gac 150 Ala Val Pro Gln Asp Leu Leu Asp 5 cag ttt gaa ctc ttt tca caa tat tcg gcg gcc gca tac tgt gcg gca 198 Gln Phe Glu Leu Phe Ser Gln Tyr Ser Ala Ala Ala Tyr Cys Ala Ala 10 15 20 aac aat cat gct cca gtg ggc tca gac gta acg tgc tcg gag aat gtc 246 Asn Asn His Ala Pro Val Gly Ser Asp Val Thr Cys Ser Glu Asn Val 25 30 35 40 tgc cct gag gta gat gcg gcg gac gca acg ttt ctc tat tct ttt gaa 294 Cys Pro Glu Val Asp Ala Ala Asp Ala Thr Phe Leu Tyr Ser Phe Glu 45 50 55 ga gtgggtgtcg acaaagcaca gagacagtag tagagacagc agtctaactg 346 Asp agatgtgcag t tct gga tta ggc gat gtt acc ggc ctt ctc gct ctc gac 396 Ser Gly Leu Gly Asp Val Thr Gly Leu Leu Ala Leu Asp 60 65 70 aac acg aat aaa ctg atc gtc ctc tct ttc cgc ggc tct cgc tca gta 444 Asn Thr Asn Lys Leu Ile Val Leu Ser Phe Arg Gly Ser Arg Ser Val 75 80 85 gag aac tgg atc gcg aac ctc gcc gcc gac ctg aca gaa ata tct gac 492 Glu Asn Trp Ile Ala Asn Leu Ala Ala Asp Leu Thr Glu Ile Ser Asp 90 95 100 atc tgc tcc ggc tgc gag ggg cat gtc ggc ttc gtt act tct tgg agg 540 Ile Cys Ser Gly Cys Glu Gly His Val Gly Phe Val Thr Ser Trp Arg 105 110 115 tct gta gcc gac act ata agg gag cag gtg cag aat gcc gtg aac gag 588 Ser Val Ala Asp Thr Ile Arg Glu Gln Val Gln Asn Ala Val Asn Glu 120 125 130 cat ccc gat tac cgc gtg gtc ttt acc gga cat agc ttg gga ggc gca 636 His Pro Asp Tyr Arg Val Val Phe Thr Gly His Ser Leu Gly Gly Ala 135 140 145 150 ctg gca act att gcc gca gca gct ctg cga gga aat gga tac aat atc 684 Leu Ala Thr Ile Ala Ala Ala Ala Leu Arg Gly Asn Gly Tyr Asn Ile 155 160 165 gac gtg gtatgtggga agaagccacc cagacaaaca attatgtgga aacatgcaag 740 Asp Val gatggctaat acacggtcca acag ttc tca tat ggc gcg ccc cgc gtc ggt 791 Phe Ser Tyr Gly Ala Pro Arg Val Gly 170 175 aac agg gca ttt gca gaa ttc ctg acc gca cag acg ggc ggc acc ctg 839 Asn Arg Ala Phe Ala Glu Phe Leu Thr Ala Gln Thr Gly Gly Thr Leu 180 185 190 tat cgc atc acc cat acc aat gat atc gtc cct aga ctc cct cct cga 887 Tyr Arg Ile Thr His Thr Asn Asp Ile Val Pro Arg Leu Pro Pro Arg 195 200 205 gac tgg ggt tac agc cac tct agc ccg gag tac tgg gtc acg tct ggt 935 Asp Trp Gly Tyr Ser His Ser Ser Pro Glu Tyr Trp Val Thr Ser Gly 210 215 220 225 aac gac gtc cca gtg acc gca aac gac atc acc gtc gtg gag ggc atc 983 Asn Asp Val Pro Val Thr Ala Asn Asp Ile Thr Val Val Glu Gly Ile 230 235 240 gat tcc acc gac ggg aac aac cag ggg aat atc cca gac atc cct tcg 1031 Asp Ser Thr Asp Gly Asn Asn Gln Gly Asn Ile Pro Asp Ile Pro Ser 245 250 255 cat cta tgg tat ttc ggt ccc att tca gag tgt gat tag 1070 His Leu Trp Tyr Phe Gly Pro Ile Ser Glu Cys Asp 260 265 6 291 PRT Thermomyces ibadanensis 6 Met Arg Ser Ser Leu Val Leu Phe Phe Leu Ser Ala Trp Thr Ala Leu -20 -15 -10 Ala Arg Pro Val Arg Arg Ala Val Pro Gln Asp Leu Leu Asp Gln Phe -5 -1 1 5 10 Glu Leu Phe Ser Gln Tyr Ser Ala Ala Ala Tyr Cys Ala Ala Asn Asn 15 20 25 His Ala Pro Val Gly Ser Asp Val Thr Cys Ser Glu Asn Val Cys Pro 30 35 40 Glu Val Asp Ala Ala Asp Ala Thr Phe Leu Tyr Ser Phe Glu Asp Ser 45 50 55 Gly Leu Gly Asp Val Thr Gly Leu Leu Ala Leu Asp Asn Thr Asn Lys 60 65 70 Leu Ile Val Leu Ser Phe Arg Gly Ser Arg Ser Val Glu Asn Trp Ile 75 80 85 90 Ala Asn Leu Ala Ala Asp Leu Thr Glu Ile Ser Asp Ile Cys Ser Gly 95 100 105 Cys Glu Gly His Val Gly Phe Val Thr Ser Trp Arg Ser Val Ala Asp 110 115 120 Thr Ile Arg Glu Gln Val Gln Asn Ala Val Asn Glu His Pro Asp Tyr 125 130 135 Arg Val Val Phe Thr Gly His Ser Leu Gly Gly Ala Leu Ala Thr Ile 140 145 150 Ala Ala Ala Ala Leu Arg Gly Asn Gly Tyr Asn Ile Asp Val Phe Ser 155 160 165 170 Tyr Gly Ala Pro Arg Val Gly Asn Arg Ala Phe Ala Glu Phe Leu Thr 175 180 185 Ala Gln Thr Gly Gly Thr Leu Tyr Arg Ile Thr His Thr Asn Asp Ile 190 195 200 Val Pro Arg Leu Pro Pro Arg Asp Trp Gly Tyr Ser His Ser Ser Pro 205 210 215 Glu Tyr Trp Val Thr Ser Gly Asn Asp Val Pro Val Thr Ala Asn Asp 220 225 230 Ile Thr Val Val Glu Gly Ile Asp Ser Thr Asp Gly Asn Asn Gln Gly 235 240 245 250 Asn Ile Pro Asp Ile Pro Ser His Leu Trp Tyr Phe Gly Pro Ile Ser 255 260 265 Glu Cys Asp 7 1064 DNA Talaromyces emersonii CDS (1)..(88) mat_peptide (88)..() CDS (142)..(310) CDS (362)..(695) CDS (756)..(1061) 7 atg ttc aaa tcg gcc gct gtg cgg gcc att gct gcc ctc gga ctg act 48 Met Phe Lys Ser Ala Ala Val Arg Ala Ile Ala Ala Leu Gly Leu Thr -25 -20 -15 gcg tca gtc ttg gct gct cct gtt gaa ctg ggc cgt cga g gtaaggaagc 98 Ala Ser Val Leu Ala Ala Pro Val Glu Leu Gly Arg Arg -10 -5 -1 atgacggaga gaacaccctg tgcgacctgc tgacatcctt cag at gtt tct cag 152 Asp Val Ser Gln gac ctc ttc gac cag ctc aat ctt ttc gag cag tac tcg gcg gct gcg 200 Asp Leu Phe Asp Gln Leu Asn Leu Phe Glu Gln Tyr Ser Ala Ala Ala 5 10 15 20 tac tgt tca gct aac aat gag gcc tct gcc ggc acg gca atc tct tgc 248 Tyr Cys Ser Ala Asn Asn Glu Ala Ser Ala Gly Thr Ala Ile Ser Cys 25 30 35 tcc gca ggc aat tgc ccg ttg gtc cag cag gct gga gca acc atc ctg 296 Ser Ala Gly Asn Cys Pro Leu Val Gln Gln Ala Gly Ala Thr Ile Leu 40 45 50 tat tca ttc aac aa gtgggtgtca cggaaaagat tgttgatacc aacatgttga 350 Tyr Ser Phe Asn Asn 55 cgtgttgtca g c att ggc tct ggc gat gtg acg ggt ttt ctc gct ctc 398 Ile Gly Ser Gly Asp Val Thr Gly Phe Leu Ala Leu 60 65 gac tcg acg aat caa ttg atc gtc ttg tca ttc cgg gga tca gag act 446 Asp Ser Thr Asn Gln Leu Ile Val Leu Ser Phe Arg Gly Ser Glu Thr 70 75 80 85 ctc gaa aac tgg atc gct gac ctg gaa gct gac ctg gtc gat gcc tct 494 Leu Glu Asn Trp Ile Ala Asp Leu Glu Ala Asp Leu Val Asp Ala Ser 90 95 100 gcc atc tgt tcc ggc tgt gaa gca cac gat ggg ttc ctt tca tcc tgg 542 Ala Ile Cys Ser Gly Cys Glu Ala His Asp Gly Phe Leu Ser Ser Trp 105 110 115 aat tca gtc gcc agc act ctg aca tcc aaa atc tcg tcg gcc gtc aac 590 Asn Ser Val Ala Ser Thr Leu Thr Ser Lys Ile Ser Ser Ala Val Asn 120 125 130 gaa cat ccc agc tac aag ctg gtc ttc acc ggc cac agt ctc gga gcc 638 Glu His Pro Ser Tyr Lys Leu Val Phe Thr Gly His Ser Leu Gly Ala 135 140 145 gcc ttg gct aca ctt gga gcc gtt tct ctt aga gag agc gga tat aat 686 Ala Leu Ala Thr Leu Gly Ala Val Ser Leu Arg Glu Ser Gly Tyr Asn 150 155 160 165 att gac ctc gtaagtttcc ggcacgggcg tcgtcatcat cgagcggaaa 735 Ile Asp Leu gactgaccgg ttaactgcag tac aat tat ggc tgc ccc cgg gtc ggt aac acc 788 Tyr Asn Tyr Gly Cys Pro Arg Val Gly Asn Thr 170 175 gcg ctc gca gac ttc atc acc acg caa tcc gga ggc aca aat tac cgc 836 Ala Leu Ala Asp Phe Ile Thr Thr Gln Ser Gly Gly Thr Asn Tyr Arg 180 185 190 195 gtc acg cat tcc gat gac cct gtc ccc aag ctg cct ccc agg agt ttt 884 Val Thr His Ser Asp Asp Pro Val Pro Lys Leu Pro Pro Arg Ser Phe 200 205 210 gga tac agc caa ccg agc cca gag tac tgg atc acc tca ggg aac aat 932 Gly Tyr Ser Gln Pro Ser Pro Glu Tyr Trp Ile Thr Ser Gly Asn Asn 215 220 225 gta act gtt caa ccg tcc gac atc gag gtc atc gaa ggc gtc gac tcc 980 Val Thr Val Gln Pro Ser Asp Ile Glu Val Ile Glu Gly Val Asp Ser 230 235 240 act gca ggc aac gac ggc acc cct gct ggc ctt gac att gat gct cat 1028 Thr Ala Gly Asn Asp Gly Thr Pro Ala Gly Leu Asp Ile Asp Ala His 245 250 255 cgg tgg tac ttt gga ccc att agc gca tgt tcg tga 1064 Arg Trp Tyr Phe Gly Pro Ile Ser Ala Cys Ser 260 265 270 8 299 PRT Talaromyces emersonii 8 Met Phe Lys Ser Ala Ala Val Arg Ala Ile Ala Ala Leu Gly Leu Thr -25 -20 -15 Ala Ser Val Leu Ala Ala Pro Val Glu Leu Gly Arg Arg Asp Val Ser -10 -5 -1 1 Gln Asp Leu Phe Asp Gln Leu Asn Leu Phe Glu Gln Tyr Ser Ala Ala 5 10 15 Ala Tyr Cys Ser Ala Asn Asn Glu Ala Ser Ala Gly Thr Ala Ile Ser 20 25 30 35 Cys Ser Ala Gly Asn Cys Pro Leu Val Gln Gln Ala Gly Ala Thr Ile 40 45 50 Leu Tyr Ser Phe Asn Asn Ile Gly Ser Gly Asp Val Thr Gly Phe Leu 55 60 65 Ala Leu Asp Ser Thr Asn Gln Leu Ile Val Leu Ser Phe Arg Gly Ser 70 75 80 Glu Thr Leu Glu Asn Trp Ile Ala Asp Leu Glu Ala Asp Leu Val Asp 85 90 95 Ala Ser Ala Ile Cys Ser Gly Cys Glu Ala His Asp Gly Phe Leu Ser 100 105 110 115 Ser Trp Asn Ser Val Ala Ser Thr Leu Thr Ser Lys Ile Ser Ser Ala 120 125 130 Val Asn Glu His Pro Ser Tyr Lys Leu Val Phe Thr Gly His Ser Leu 135 140 145 Gly Ala Ala Leu Ala Thr Leu Gly Ala Val Ser Leu Arg Glu Ser Gly 150 155 160 Tyr Asn Ile Asp Leu Tyr Asn Tyr Gly Cys Pro Arg Val Gly Asn Thr 165 170 175 Ala Leu Ala Asp Phe Ile Thr Thr Gln Ser Gly Gly Thr Asn Tyr Arg 180 185 190 195 Val Thr His Ser Asp Asp Pro Val Pro Lys Leu Pro Pro Arg Ser Phe 200 205 210 Gly Tyr Ser Gln Pro Ser Pro Glu Tyr Trp Ile Thr Ser Gly Asn Asn 215 220 225 Val Thr Val Gln Pro Ser Asp Ile Glu Val Ile Glu Gly Val Asp Ser 230 235 240 Thr Ala Gly Asn Asp Gly Thr Pro Ala Gly Leu Asp Ile Asp Ala His 245 250 255 Arg Trp Tyr Phe Gly Pro Ile Ser Ala Cys Ser 260 265 270 9 1074 DNA Talaromyces byssochlamydoides CDS (1)..(85) mat_peptide (85)..() CDS (150)..(318) CDS (376)..(709) CDS (760)..(1071) 9 atg ttc aaa tca act gtc cgg gcc atc gcc gcc ctc gga ctg acc tcg 48 Met Phe Lys Ser Thr Val Arg Ala Ile Ala Ala Leu Gly Leu Thr Ser -25 -20 -15 tca gtc ttt gct gct cct atc gaa ctg ggc cgt cga g gtaaggggca 95 Ser Val Phe Ala Ala Pro Ile Glu Leu Gly Arg Arg -10 -5 -1 tgaaaactcc ctgtatggca tctcatctgg cagcatatct actgacatcc tcag at 151 Asp gtt tcg gag cag ctc ttc aac cag ttc aat ctc ttc gag cag tat tcc 199 Val Ser Glu Gln Leu Phe Asn Gln Phe Asn Leu Phe Glu Gln Tyr Ser 5 10 15 gcg gct gcg tac tgt cca gcc aac ttt gag tcc gct tcc ggc gcg gca 247 Ala Ala Ala Tyr Cys Pro Ala Asn Phe Glu Ser Ala Ser Gly Ala Ala 20 25 30 att tct tgt tcc aca ggc aat tgc ccg ctc gtc caa cag gct ggc gca 295 Ile Ser Cys Ser Thr Gly Asn Cys Pro Leu Val Gln Gln Ala Gly Ala 35 40 45 acc acc ctg tat gca ttc aac aa gtgagtgtca tggaaaggct tgttggtaca 348 Thr Thr Leu Tyr Ala Phe Asn Asn 50 55 ccgtacgggt atgttgactg tcatcag c atc ggc tct ggc gat gtg acg ggt 400 Ile Gly Ser Gly Asp Val Thr Gly 60 65 ttt ctt gct gtc gat ccg acc aac cga ctc atc gtc ttg tcg ttc cgg 448 Phe Leu Ala Val Asp Pro Thr Asn Arg Leu Ile Val Leu Ser Phe Arg 70 75 80 ggg tca gag agt ctc gag aac tgg atc act aat ctc agc gcc gac ctg 496 Gly Ser Glu Ser Leu Glu Asn Trp Ile Thr Asn Leu Ser Ala Asp Leu 85 90 95 gtc gat gcc tct gca atc tgt tcc ggg tgt gaa gcc cat gac gga ttc 544 Val Asp Ala Ser Ala Ile Cys Ser Gly Cys Glu Ala His Asp Gly Phe 100 105 110 tat tcg tct tgg caa tca gtt gcc agc act ctg acc tcc caa atc tcg 592 Tyr Ser Ser Trp Gln Ser Val Ala Ser Thr Leu Thr Ser Gln Ile Ser 115 120 125 tcg gcc ctc tcg gca tat cca aac tac aag ctg gtc ttc acc ggc cac 640 Ser Ala Leu Ser Ala Tyr Pro Asn Tyr Lys Leu Val Phe Thr Gly His 130 135 140 145 agt ctc gga gcc gcc tta gct aca ctt gga gct gtc tct ctc agg gag 688 Ser Leu Gly Ala Ala Leu Ala Thr Leu Gly Ala Val Ser Leu Arg Glu 150 155 160 agt gga tac aat atc gac ctc gtaagttcct ggcattgcca tcatggaaag 739 Ser Gly Tyr Asn Ile Asp Leu 165 agactcacag ttaactgtag tac aac ttt ggc tgt ccc cgg gtc ggc aac act 792 Tyr Asn Phe Gly Cys Pro Arg Val Gly Asn Thr 170 175 gcg ctc gca gac ttt att acc aac caa acc ggt ggc aca aat tac cgg 840 Ala Leu Ala Asp Phe Ile Thr Asn Gln Thr Gly Gly Thr Asn Tyr Arg 180 185 190 195 gta acg cat tac gag gac cct gtc ccc aag ctg cct ccc agg agt ttt 888 Val Thr His Tyr Glu Asp Pro Val Pro Lys Leu Pro Pro Arg Ser Phe 200 205 210 gga tac agc caa cct agc ccg gaa tac tgg atc acg tcg gga aac aat 936 Gly Tyr Ser Gln Pro Ser Pro Glu Tyr Trp Ile Thr Ser Gly Asn Asn 215 220 225 gtg act gtg act tcg tcc gac atc gat gtc gtc gtg ggt gtc gac tcg 984 Val Thr Val Thr Ser Ser Asp Ile Asp Val Val Val Gly Val Asp Ser 230 235 240 act gca ggc aac gac ggg acg cct gat ggc ctt gac act gct gcc cat 1032 Thr Ala Gly Asn Asp Gly Thr Pro Asp Gly Leu Asp Thr Ala Ala His 245 250 255 agg tgg tat ttt gga cct act acc gaa tgt tcg tcg tca tga 1074 Arg Trp Tyr Phe Gly Pro Thr Thr Glu Cys Ser Ser Ser 260 265 270 10 300 PRT Talaromyces byssochlamydoides 10 Met Phe Lys Ser Thr Val Arg Ala Ile Ala Ala Leu Gly Leu Thr Ser -25 -20 -15 Ser Val Phe Ala Ala Pro Ile Glu Leu Gly Arg Arg Asp Val Ser Glu -10 -5 -1 1 Gln Leu Phe Asn Gln Phe Asn Leu Phe Glu Gln Tyr Ser Ala Ala Ala 5 10 15 20 Tyr Cys Pro Ala Asn Phe Glu Ser Ala Ser Gly Ala Ala Ile Ser Cys 25 30 35 Ser Thr Gly Asn Cys Pro Leu Val Gln Gln Ala Gly Ala Thr Thr Leu 40 45 50 Tyr Ala Phe Asn Asn Ile Gly Ser Gly Asp Val Thr Gly Phe Leu Ala 55 60 65 Val Asp Pro Thr Asn Arg Leu Ile Val Leu Ser Phe Arg Gly Ser Glu 70 75 80 Ser Leu Glu Asn Trp Ile Thr Asn Leu Ser Ala Asp Leu Val Asp Ala 85 90 95 100 Ser Ala Ile Cys Ser Gly Cys Glu Ala His Asp Gly Phe Tyr Ser Ser 105 110 115 Trp Gln Ser Val Ala Ser Thr Leu Thr Ser Gln Ile Ser Ser Ala Leu 120 125 130 Ser Ala Tyr Pro Asn Tyr Lys Leu Val Phe Thr Gly His Ser Leu Gly 135 140 145 Ala Ala Leu Ala Thr Leu Gly Ala Val Ser Leu Arg Glu Ser Gly Tyr 150 155 160 Asn Ile Asp Leu Tyr Asn Phe Gly Cys Pro Arg Val Gly Asn Thr Ala 165 170 175 180 Leu Ala Asp Phe Ile Thr Asn Gln Thr Gly Gly Thr Asn Tyr Arg Val 185 190 195 Thr His Tyr Glu Asp Pro Val Pro Lys Leu Pro Pro Arg Ser Phe Gly 200 205 210 Tyr Ser Gln Pro Ser Pro Glu Tyr Trp Ile Thr Ser Gly Asn Asn Val 215 220 225 Thr Val Thr Ser Ser Asp Ile Asp Val Val Val Gly Val Asp Ser Thr 230 235 240 Ala Gly Asn Asp Gly Thr Pro Asp Gly Leu Asp Thr Ala Ala His Arg 245 250 255 260 Trp Tyr Phe Gly Pro Thr Thr Glu Cys Ser Ser Ser 265 270 11 51 DNA Artificial Sequence misc_feature 051200j1 11 ggggacaagt ttgtacaaaa aagcaggacc atgaggagct cgctcgtgct g 51 12 39 DNA Artificial Sequence misc_feature 051200J2 12 ccagtcctgt ccgacgagag gtctcgcagg atctgtttg 39 13 39 DNA Artificial Sequence misc_feature 051200J3 13 caaacagatc ctgcgagacc tctcgtcgga caggactgg 39 14 39 DNA Artificial Sequence misc_feature 051200J4 14 tctctactcg tttgaggatt ctggagttgg cgatgtcac 39 15 36 DNA Artificial Sequence misc_feature 051200J5 15 acatcgccaa ctccagaatc ctcaaacgag tagaga 36 16 36 DNA Artificial Sequence misc_feature 051200J6 16 gggtacgata tagatgtgtt ctcatatggc gctccc 36 17 36 DNA Artificial Sequence misc_feature 051200J7 17 gggagcgcca tatgagaaca catctatatc gtaccc 36 18 48 DNA Artificial Sequence misc_feature 051200J8 18 ggggaccact ttgtacaaga aagctggtta caaacacgtc gccattga 48 19 51 DNA Artificial Sequence misc_feature 051200J9 19 ggggacaagt ttgtacaaaa aagcaggacc atgttcaaat cggccgctgt g 51 20 42 DNA Artificial Sequence misc_feature 051200J10 20 ctgttgaact gggccgtcga gatgtttctc aggacctctt cg 42 21 42 DNA Artificial Sequence misc_feature 051200J11 21 cgaagaggtc ctgagaaaca tctcgacggc ccagttcaac ag 42 22 42 DNA Artificial Sequence misc_feature 051200J12 22 catcctgtat tcattcaaca acattggctc tggcgatgtg ac 42 23 42 DNA Artificial Sequence misc_feature 051200J13 23 gtcacatcgc cagagccaat gttgttgaat gaatacagga tg 42 24 42 DNA Artificial Sequence misc_feature 051200J14 24 agcggatata atattgacct ctacaattat ggctgccccc gg 42 25 42 DNA Artificial Sequence misc_feature 051200J15 25 ccgggggcag ccataattgt agaggtcaat attatatccg ct 42 26 48 DNA Artificial Sequence misc_feature 051200J16 26 ggggaccact ttgtacaaga aagctggtca cgaacatgcg ctaatggg 48 27 51 DNA Artificial Sequence misc_feature 051200J17 27 ggggacaagt ttgtacaaaa aagcaggacc atgcggagct ccctcgtgct g 51 28 42 DNA Artificial Sequence misc_feature 051200J18 28 tggcgcggcc tgttcgacga gcggttccgc aagatctgct cg 42 29 42 DNA Artificial Sequence misc_feature 051200J19 29 cgagcagatc ttgcggaacc gctcgtcgaa caggccgcgc ca 42 30 42 DNA Artificial Sequence misc_feature 051200J20 30 gtttctctat tcttttgaag attctggatt aggcgatgtt ac 42 31 42 DNA Artificial Sequence misc_feature 051200J21 31 gtaacatcgc ctaatccaga atcttcaaaa gaatagagaa ac 42 32 42 DNA Artificial Sequence misc_feature 051200J22 32 aatggataca atatcgacgt gttctcatat ggcgcgcccc gc 42 33 42 DNA Artificial Sequence misc_feature 051200J23 33 gcggggcgcg ccatatgaga acacgtcgat attgtatcca tt 42 34 48 DNA Artificial Sequence misc_feature 051200J24 34 ggggaccact ttgtacaaga aagctggcta atcacactct gaaatggg 48 35 31 DNA Artificial Sequence misc_feature 142779 35 ttgaattgaa aatagattga tttaaaactt c 31 36 25 DNA Artificial Sequence misc_feature 142780 36 ttgcatgcgt aatcatggtc atagc 25 37 26 DNA Artificial Sequence misc_feature 140288 37 ttgaattcat gggtaataac tgatat 26 38 32 DNA Artificial Sequence misc_feature 142778 38 aaatcaatct attttcaatt caattcatca tt 32 39 11 DNA Artificial Sequence misc_feature gtactaaaacc 39 gtactaaaac c 11 40 11 DNA Artificial Sequence misc_feature ccgttaaattt 40 ccgttaaatt t 11 41 45 DNA Artificial Sequence misc_feature 141223 41 ggatgctgtt gactccggaa atttaacggt ttggtcttgc atccc 45 42 14 DNA Artificial Sequence misc_feature atgcaatttaaact 42 atgcaattta aact 14 43 14 DNA Artificial Sequence misc_feature cggcaatttaacgg 43 cggcaattta acgg 14 44 44 DNA Artificial Sequence misc_feature 141222 44 ggtattgtcc tgcagacggc aatttaacgg cttctgcgaa tcgc 44 45 59 DNA Artificial Sequence misc_feature 051199J1 45 cctctagatc tcgagctcgg tcaccggtgg cctccgcggc cgctggatcc ccagttgtg 59 46 33 DNA Artificial Sequence misc_feature 1298TAKA 46 gcaagcgcgc gcaatacatg gtgttttgat cat 33 47 30 DNA Artificial Sequence misc_feature 177996 47 gaatgacttg gttgacgcgt caccagtcac 30 48 25 DNA Artificial Sequence misc_feature 135640 48 cttattagta ggttggtact tcgag 25 49 37 DNA Artificial Sequence misc_feature 135638 49 gtccccagag tagtgtcact atgtcgaggc agttaag 37 50 64 DNA Artificial Sequence misc_feature 080399J19 50 gtatgtccct tgacaatgcg atgtatcaca tgatataatt actagcaagg gaagccgtgc 60 ttgg 64 51 18 DNA Artificial Sequence misc_feature HL 2 51 wsngcngcng cntaytgy 18 52 28 DNA Artificial Sequence misc_feature HL 12 52 ggnacnrkrt crttnnnrtg ngtnaync 28 53 26 DNA Artificial Sequence misc_feature HL 6 53 avngcnccnc cnarnswrtg nccngt 26

Claims (17)

1. A method of producing a lipolytic enzyme which comprises:
a) shuffling at least two polynucleotides which comprise:
i) a polynucleotide encoding a polypeptide which has lipolytic enzyme activity and has an amino acid sequence having at least 90% identity with the mature peptide of SEQ ID NO: 2, and
ii) a polynucleotide encoding a polypeptide which has lipolytic enzyme activity and has an amino acid sequence having 55-90% identity with the mature peptide of SEQ ID NO: 2
b) expressing the shuffled polynucleotides to form recombinant polypeptides,
c) screening the polypeptides to select a polypeptide having lipolytic enzyme activity, and
d) producing the selected polypeptide.
2. The method of claim 1 wherein the amino acid sequence encoded by polynucleotide (ii) has at least 90% identity to the mature part of SEQ ID NO: 4, 6, 8 or 10.
3. The method of claim 1 or 2 wherein the polynucleotides comprise a polynucleotide having a nucleotide sequence having at least 90% identity to the mature part of SEQ ID NO: 1, 3, 5, 7 or 9.
4. A polynucleotide which comprises a nucleotide sequence which encodes a lipolytic enzyme and which:
a) is a DNA sequence cloned into a plasmid present in Escherichia coli deposit number DSM 14047, 14048,14049, or 14051, or
b) is the DNA sequence encoding a mature peptide shown in SEQ ID NO: 3, 5, 7 or 9 or can be derived therefrom by substitution, deletion, and/or insertion of one or more nucleotides, or
c) has at least 90% identity with the DNA sequence encoding a mature peptide shown in SEQ ID NO: 3, at least 80% identity with the DNA sequence encoding a mature peptide shown in SEQ ID NO: 5, at least 65% identity with the DNA sequence encoding a mature peptide shown in SEQ ID NO: 7 or at least 60% identity with the DNA sequence encoding a mature peptide shown in SEQ ID NO: 9, or
d) is an allelic variant of the DNA sequence encoding a mature peptide shown in SEQ ID NO: 3, 5, 7 or 9; or
e) hybridizes under high stringency conditions with a complementary strand of the nucleic acid sequence encoding a mature peptide shown in SEQ ID NO: 3, 5, 7 or 9, or a subsequence thereof having at least 100 nucleotides.
5. The polynucleotide of claim 4 which further comprises one or more control sequences which are operably linked to said nucleotide sequence and capable of directing the expression of the lipolytic enzyme in a suitable expression host.
6. A recombinant expression vector comprising the polynucleotide of claim 5, a promoter, and transcriptional and translational stop signals.
7. A recombinant host cell transformed with the polynucleotide of claim 5 or the vector of claim 6.
8. A method for producing a polypeptide having lipolytic enzyme activity comprising cultivating the host cell of claim 7 under conditions conducive to production of the polypeptide, and recovering the polypeptide.
9. A polypeptide which has lipolytic enzyme activity and which:
f) is encoded by a DNA sequence cloned into a plasmid present in Escherichia coli deposit number DSM 14047 or 14049, or
g) has an amino acid sequence which is the mature peptide of SEQ ID NO: 6 or 10, or can be derived therefrom by substitution, deletion, and/or insertion of one or more amino acids, or
h) has an amino acid sequence which has at least 80% identity with the mature peptide of SEQ ID NO: 6 or at least 60% identity with the mature peptide of SEQ ID NO: 10, or
i) is immunologically reactive with an antibody raised against the mature peptide of SEQ ID NO: 6 or 10 in purified form, or
j) is an allelic variant of the mature peptide of SEQ ID NO: 6 or 10; or
k) is encoded by a nucleic acid sequence which hybridizes under high stringency conditions with a complementary strand of the nucleic acid sequence encoding a mature peptide shown in SEQ ID NO: 5 or 9, or a subsequence thereof having at least 100 nucleotides.
10. The polypeptide of claim 9 which is native to a strain of Talaromyces or Thermomyces, particularly Thermomyces ibadanensis or Talaromyces byssochlamydoides.
11. A nucleic acid sequence comprising a nucleic acid sequence which encodes the polypeptide of claim 9 or 10.
12. A process for hydrolyzing the fatty acyl group in a lysophospholipid, comprising treating the lysophospholipid with a polypeptide which has lysophospholipase activity and which:
a) is encoded by a DNA sequence cloned into a plasmid present in Escherichia coli deposit number DSM 14047, 14048, 14049 or 14051, or
b) has an amino acid sequence which is the mature peptide of SEQ ID NO: 4, 6, 8 or 10, or can be derived therefrom by substitution, deletion, and/or insertion of one or more amino acids, or
c) has an amino acid sequence which has at least 55% identity with the mature peptide of SEQ ID NO: 4, 6, 8 or 10, or
d) is immunologically reactive with an antibody raised against the mature peptide of SEQ ID NO: 4, 6, 8 or 10 in purified form, or
e) is an allelic variant of the mature peptide of SEQ ID NO: 4, 6, 8 or 10; or
f) is encoded by a nucleic acid sequence which hybridizes under high stringency conditions with a complementary strand of the nucleic acid sequence encoding a mature peptide shown in SEQ ID NO: 3, 5, 7 or 9, or a subsequence thereof having at least 100 nucleotides.
13. A process according to claim 12 for improving the filterability of an aqueous solution or slurry of carbohydrate origin which contains lysophospholipid.
14. The process of the preceding claim wherein the solution or slurry contains a starch hydrolysate, particularly a wheat starch hydrolysate.
15. A detergent composition comprising a surfactant and a polypeptide which has lipolytic enzyme activity and which:
a) is encoded by a DNA sequence cloned into a plasmid present in Escherichia coli deposit number DSM 14047, 14048, 14049 or 14051, or
b) has an amino acid sequence which is the mature peptide of SEQ ID NO: 4, 6, 8 or 10, or can be derived therefrom by substitution, deletion, and/or insertion of one or more amino acids, or
c) has an amino acid sequence which has at least 55% identity with the mature peptide of SEQ ID NO: 4, 6, 8 or 10, or
d) is immunologically reactive with an antibody raised against the mature peptide of SEQ ID NO: 4, 6, 8 or 10 in purified form, or
e) is an allelic variant of the mature peptide of SEQ ID NO: 4, 6, 8 or 10; or
f) is encoded by a nucleic acid sequence which hybridizes under high stringency conditions with a complementary strand of the nucleic acid sequence encoding a mature peptide shown in SEQ ID NO: 3, 5, 7 or 9, or a subsequence thereof having at least 100 nucleotides.
16. A flour composition comprising flour and a polypeptide which has lipolytic enzyme activity and which:
a) is encoded by a DNA sequence cloned into a plasmid present in Escherichia coli deposit number DSM 14047, 14048, 14049 or 14051, or
b) has an amino acid sequence which is the mature peptide of SEQ ID NO: 4, 6, 8 or 10, or can be derived therefrom by substitution, deletion, and/or insertion of one or more amino acids, or
c) has an amino acid sequence which has at least 55% identity with the mature peptide of SEQ ID NO: 4, 6, 8 or 10, or
d) is immunologically reactive with an antibody raised against the mature peptide of SEQ ID NO: 4, 6, 8 or 10 in purified form, or
e) is an allelic variant of the mature peptide of SEQ ID NO: 4, 6, 8 or 10; or
f) is encoded by a nucleic acid sequence which hybridizes under high stringency conditions with a complementary strand of the nucleic acid sequence encoding a mature peptide shown in SEQ ID NO: 3, 5, 7 or 9, or a subsequence thereof having at least 100 nucleotides.
17. A process for producing a dough or a baked product made from dough, comprising adding to the dough a polypeptide which has lipolytic enzyme activity and which:
g) is encoded by a DNA sequence cloned into a plasmid present in Escherichia coli deposit number DSM 14047, 14048, 14049 or 14051, or
h) has an amino acid sequence which is the mature peptide of SEQ ID NO: 4, 6, 8 or 10, or can be derived therefrom by substitution, deletion, and/or insertion of one or more amino acids, or
i) has an amino acid sequence which has at least 55% identity with the mature peptide of SEQ ID NO: 4, 6, 8 or 10, or
j) is immunologically reactive with an antibody raised against the mature peptide of SEQ ID NO: 4, 6, 8 or 10 in purified form, or
k) is an allelic variant of the mature peptide of SEQ ID NO: 4, 6, 8 or 10; or
l) is encoded by a nucleic acid sequence which hybridizes under high stringency conditions with a complementary strand of the nucleic acid sequence encoding a mature peptide shown in SEQ ID NO: 3, 5, 7 or 9, or a subsequence thereof having at least 100 nucleotides.
US10/250,824 2001-02-23 2002-02-25 Lipolytic enzyme genes Abandoned US20040101928A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/474,151 US7271139B2 (en) 2001-02-23 2006-06-23 Lipolytic enzyme genes

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200100304 2001-02-23
DKPA200100304 2001-02-23
PCT/DK2002/000124 WO2002066622A2 (en) 2001-02-23 2002-02-25 Method of generating diversity into lipolytic enzymes and lipolytic enzyme genes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/474,151 Continuation US7271139B2 (en) 2001-02-23 2006-06-23 Lipolytic enzyme genes

Publications (1)

Publication Number Publication Date
US20040101928A1 true US20040101928A1 (en) 2004-05-27

Family

ID=8160293

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/250,824 Abandoned US20040101928A1 (en) 2001-02-23 2002-02-25 Lipolytic enzyme genes
US11/474,151 Expired - Fee Related US7271139B2 (en) 2001-02-23 2006-06-23 Lipolytic enzyme genes

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/474,151 Expired - Fee Related US7271139B2 (en) 2001-02-23 2006-06-23 Lipolytic enzyme genes

Country Status (7)

Country Link
US (2) US20040101928A1 (en)
EP (1) EP1404827A2 (en)
JP (2) JP2004522448A (en)
CN (1) CN1526013A (en)
AU (1) AU2002234513B2 (en)
CA (1) CA2432375C (en)
WO (1) WO2002066622A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080182322A1 (en) * 2007-01-30 2008-07-31 Dayton Christopher L G Enzymatic Degumming Utilizing a Mixture of PLA and PLC Phospholipases
US20090069587A1 (en) * 2007-09-11 2009-03-12 Dayton Christopher L G Enzymatic Degumming Utilizing a Mixture of PLA and PLC Phospholipases with Reduced Reaction Time
US8241876B2 (en) 2008-01-07 2012-08-14 Bunge Oils, Inc. Generation of triacylglycerols from gums

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0112226D0 (en) 2001-05-18 2001-07-11 Danisco Method of improving dough and bread quality
US8178090B2 (en) 1995-06-07 2012-05-15 Danisco A/S Recombinant hexose oxidase
US6936289B2 (en) 1995-06-07 2005-08-30 Danisco A/S Method of improving the properties of a flour dough, a flour dough improving composition and improved food products
EP1020523A3 (en) 1995-06-07 2000-08-30 Bioteknologisk Institut Recombinant hexose oxidase, a method of producing same and use of such enzyme
CN1080536C (en) 1995-06-07 2002-03-13 丹尼司可公司 Method of improving the properties of a flour dough, a flour dough improving composition and improved food products
US7745599B1 (en) 1995-06-07 2010-06-29 Danisco A/S Hexose oxidase-encoding DNAs and methods of use thereof
DE60220155T2 (en) 2001-05-18 2008-02-07 Danisco A/S PROCESS FOR PREPARING DOUGH WITH AN ENZYME
EP1803353A3 (en) * 2001-05-18 2007-07-18 Danisco A/S Method of preparing a dough with an enzyme
ATE494368T1 (en) 2002-10-01 2011-01-15 Novozymes As POLYPEPTIDES OF THE GH-61 FAMILY
CA2538349C (en) 2003-06-25 2014-08-12 Novozymes A/S Polypeptides having alpha-amylase activity and polynucleotides encoding same
AU2005263954B2 (en) 2004-07-16 2011-04-07 Dupont Nutrition Biosciences Aps Enzymatic oil-degumming method
DE602005025038D1 (en) 2004-12-22 2011-01-05 Novozymes As SEAMINOACE SEQUENCE AND A CARBOHYDRATE BINDING MODULE AS A SECOND AMINO ACID SEQUENCE
EP1851311A2 (en) * 2005-02-10 2007-11-07 Novozymes A/S Enzymatic enantioselective ester or amide hydrolysis or synthesis
CN103451164A (en) * 2006-07-14 2013-12-18 诺维信股份有限公司 Methods for producing secreted polypeptides having biological activity
EP2044188B1 (en) * 2006-07-14 2015-09-09 Novozymes A/S Polypeptides having lipase activity and polynucleotides encoding same
DE102006046719A1 (en) 2006-10-02 2008-04-03 Ab Enzymes Gmbh DNA sequence coding for an Aspergillus fumigatus phospholipase, e.g. useful for desliming vegetable oil
DE102006046857A1 (en) 2006-10-02 2008-04-03 Ab Enzymes Gmbh DNA sequence coding for an Aspergillus fumigatus lysophospholipase, e.g. useful for improving the filtration of sugar syrups
EP2132292B1 (en) 2007-04-09 2014-10-08 Novozymes A/S An enzymatic treatment of skin and hide degreasing
CN102666824A (en) 2009-12-21 2012-09-12 丹尼斯科美国公司 Surfactants that improve the cleaning of lipid-based stains
US8765425B2 (en) 2011-03-23 2014-07-01 Butamax Advanced Biofuels Llc In situ expression of lipase for enzymatic production of alcohol esters during fermentation
US8759044B2 (en) 2011-03-23 2014-06-24 Butamax Advanced Biofuels Llc In situ expression of lipase for enzymatic production of alcohol esters during fermentation
JP6216495B2 (en) * 2011-04-19 2017-10-18 三菱ケミカルフーズ株式会社 Production method of puffed food
US9949409B2 (en) * 2016-05-11 2018-04-17 Facebook, Inc. Modular network switches, associated structures, and associated methods of manufacture and use
CA3046824A1 (en) * 2016-12-14 2018-06-21 Wageningen Universiteit Thermostable cas9 nucleases
CN106676084B (en) * 2017-02-09 2019-11-29 浙江工业大学 A kind of lipase mutant, encoding gene and its application from thermophilic ankle section bacterium
CN112175967B (en) * 2020-10-10 2021-10-29 安徽农业大学 PEN1 gene for enhancing plant resistance to lepidoptera pests and application thereof
CN112175976B (en) * 2020-11-12 2021-12-28 武汉轻工大学 High-temperature-resistant lipase gene tllgold and application thereof
CN117916366A (en) * 2021-08-30 2024-04-19 天野酶制品株式会社 Transesterification enzyme agent containing lipase as active ingredient
WO2023203080A1 (en) 2022-04-20 2023-10-26 Novozymes A/S Process for producing free fatty acids
WO2023225459A2 (en) 2022-05-14 2023-11-23 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275011A (en) * 1978-12-20 1981-06-23 Ajinomoto Company, Incorporated Method of producing improved glyceride by lipase
US5869438A (en) * 1990-09-13 1999-02-09 Novo Nordisk A/S Lipase variants
US5976855A (en) * 1994-02-22 1999-11-02 Novo Nordisk A/S Method of preparing a variant of a lipolytic enzyme
US6140094A (en) * 1997-01-16 2000-10-31 Rohm Gmbh Protein with phospholipase activity
US6159687A (en) * 1997-03-18 2000-12-12 Novo Nordisk A/S Methods for generating recombined polynucleotides
US20040053360A1 (en) * 2001-02-07 2004-03-18 Signe Munk Lipase variants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2058119T3 (en) 1986-08-29 1994-11-01 Novo Nordisk As ENZYMATIC DETERGENT ADDITIVE.
WO1992019726A1 (en) * 1991-05-01 1992-11-12 Novo Nordisk A/S Stabilized enzymes
EP0575133B2 (en) 1992-06-16 2008-06-18 Sankyo Lifetech Company Limited Novel phospholipase A1, process for its preparation and the use thereof
JP4307549B2 (en) 1995-07-14 2009-08-05 ノボザイムス アクティーゼルスカブ Modified enzyme with lipolytic activity
EP0843725B1 (en) * 1995-08-11 2002-04-17 Novozymes A/S Method for preparing polypeptide variants
DE69840382D1 (en) * 1997-03-18 2009-02-05 Novozymes As METHOD FOR THE PRODUCTION OF A LIBRARY THROUGH DNA SHUFFLING
EP1721527B1 (en) 1997-04-09 2010-06-09 Danisco A/S Lipase and use of same for improving doughs and baked products
DK1131416T3 (en) * 1998-11-27 2009-10-26 Novozymes As Lipolytic Enzyme Variants

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275011A (en) * 1978-12-20 1981-06-23 Ajinomoto Company, Incorporated Method of producing improved glyceride by lipase
US5869438A (en) * 1990-09-13 1999-02-09 Novo Nordisk A/S Lipase variants
US5976855A (en) * 1994-02-22 1999-11-02 Novo Nordisk A/S Method of preparing a variant of a lipolytic enzyme
US6140094A (en) * 1997-01-16 2000-10-31 Rohm Gmbh Protein with phospholipase activity
US6159687A (en) * 1997-03-18 2000-12-12 Novo Nordisk A/S Methods for generating recombined polynucleotides
US20040053360A1 (en) * 2001-02-07 2004-03-18 Signe Munk Lipase variants

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080182322A1 (en) * 2007-01-30 2008-07-31 Dayton Christopher L G Enzymatic Degumming Utilizing a Mixture of PLA and PLC Phospholipases
US8956853B2 (en) 2007-01-30 2015-02-17 Bunge Oils, Inc. Enzymatic degumming utilizing a mixture of PLA and PLC phospholipases
US20090069587A1 (en) * 2007-09-11 2009-03-12 Dayton Christopher L G Enzymatic Degumming Utilizing a Mixture of PLA and PLC Phospholipases with Reduced Reaction Time
US8460905B2 (en) 2007-09-11 2013-06-11 Bunge Oils, Inc. Enzymatic degumming utilizing a mixture of PLA and PLC phospholipases with reduced reaction time
US8241876B2 (en) 2008-01-07 2012-08-14 Bunge Oils, Inc. Generation of triacylglycerols from gums
US8541211B2 (en) 2008-01-07 2013-09-24 Bunge Oils, Inc. Generation of triacylglycerols

Also Published As

Publication number Publication date
AU2002234513B2 (en) 2006-12-07
CA2432375A1 (en) 2002-08-29
WO2002066622A3 (en) 2004-01-08
JP2008035867A (en) 2008-02-21
EP1404827A2 (en) 2004-04-07
US7271139B2 (en) 2007-09-18
JP2004522448A (en) 2004-07-29
CN1526013A (en) 2004-09-01
US20070010418A1 (en) 2007-01-11
WO2002066622A2 (en) 2002-08-29
JP4130693B2 (en) 2008-08-06
CA2432375C (en) 2015-09-08

Similar Documents

Publication Publication Date Title
US7271139B2 (en) Lipolytic enzyme genes
AU2002234513A1 (en) Method of generating diversity into lipolytic enzymes and lipolytic enzyme genes
EP2119773A1 (en) Lipolytic enzymes from strains of fusarium and acremonium
EP1360278B1 (en) Lipase variants
US7226770B2 (en) Lipolytic enzyme variant
US6645749B2 (en) Lipolytic enzyme
US7781200B2 (en) Polypeptides having lipase activity and polynucleotides encoding same
US6506588B2 (en) Lipolytic enzymes
US6511837B2 (en) Lipolytic enzymes
US6509182B2 (en) Lipolytic enzymes
HUT71315A (en) Modified cutinases, dna, vector and host
HUT74267A (en) Detergent compositions containing enzime
CA2150837A1 (en) Modified cutinases, dna, vector and host
WO2002024881A1 (en) Phospholipase from zygoascus hellenicus
CA2334041A1 (en) Enzyme with xylanase activity

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVOZYMES A/S, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TSUTSUMI, NORIKO;VIND, JESPER;PATKAR, SHAMKANT ANANT;REEL/FRAME:014938/0149;SIGNING DATES FROM 20030613 TO 20030616

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE